Original Article
Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against Endotoxin — A Randomized, Double-Blind, Placebo-Controlled Trial
N Engl J Med 1991; 324:429-436February 14, 1991
- Abstract
Background.
HA-1A is a human monoclonal IgM antibody that binds specifically to the lipid A domain of endotoxin and prevents death in laboratory animals with gram-negative bacteremia and endotoxemia.
Methods.
To evaluate the efficacy and safety of HA-1A, we conducted a randomized, double-blind trial in patients with sepsis and a presumed diagnosis of gram-negative infection. The patients received either a single 100-mg intravenous dose of HA-1A(in 3.5 g of albumin) or placebo (3.5 g of albumin). Other interventions, including the administration of antibiotics and fluids, were not affected by the study protocol.
Results.
Of 543 patients with sepsis who were treated, 200 (37 percent) had gram-negative bacteremia as proved by blood culture. For the patients with gram-negative bacteremia followed to death or day 28, there were 45 deaths among the 92 recipients of placebo (49 percent) and 32 deaths among the 105 recipients of HA-1A (30 percent; P = 0.014). For the patients with gram-negative bacteremia and shock at entry, there were 27 deaths among the 47 recipients of placebo (57 percent) and 18 deaths among the 54 recipients of HA-1A (33 percent; P = 0.017). Analyses that stratified according to the severity of illness at entry showed improved survival with HA-1A treatment in both severely ill and less severely ill patients. Of the 196 patients with gram-negative bacteremia who were followed to hospital discharge or death, 45 of the 93 given placebo (48 percent) were discharged alive, as compared with 65 of the 103 treated with HA-1A (63 percent; P = 0.038). No benefit of treatment with HA-1A was demonstrated in the 343 patients with sepsis who did not prove to have gram-negative bacteremia. For all 543 patients with sepsis who were treated, the mortality rate was 43 percent among the recipients of placebo and 39 percent among those given HA-1A (P = 0.24). All patients tolerated HA-1A well, and no anti—HA-1A antibodies were detected.
Conclusions.
HA-1A is safe and effective for the treatment of patients with sepsis and gram-negative bacteremia. (N Engl J Med 1991; 324:429–36.)
Media in This Article
Figure 1
Probability of Survival in Patients with Gram-Negative Bacteremia.Figure 2
Probability of Survival in Patients with Gram-Negative Bacteremia and Shock at Entry.Article Activity
- Article
Septicemia is a leading cause of morbidity and mortality among hospitalized patients. There are approximately 400,000 cases each year in the United States, and the incidence continues to increase.1 Gram-negative bacteremia occurs in about 30 percent of patients with septicemia.2 Despite the use of potent antibiotics and intensive supportive care, the mortality among patients with sepsis and gram-negative bacteremia remains high. It varies from 20 to 60 percent, depending on the specific population.2 3 4
Bacteremia and septic shock are associated with the release of endotoxin into the circulation.5 , 6 Endotoxin is the lipopolysaccharide component of the cell walls of gram-negative bacteria that triggers many of the adverse systemic reactions and serious sequelae in patients with sepsis and gram-negative bacteremia. Immunotherapy with human polyclonal antiserum or plasma directed against endotoxin core determinants has been shown in trials to reduce mortality in patients with gram-negative bacteremia7 and to protect high-risk surgical patients from septic shock.8 The antiserum used in those trials was developed by immunizing volunteers with heat-inactivated cells of the J5 mutant of Escherichia coli 0111:B4, which induce an immune response to the core region of endotoxin. The region is shared among gram-negative bacterial The HA-1A Sepsis Study Group was as follows: Participating Centers: University of Miami, Veterans Affairs Medical Center, and Jackson Memorial Medical Center — Charles L. Sprung, M.D. (principal investigator), Maria Peña, R.N., M.S.N., Daniel H. Kett, M.D., Bernard Elser, M.D., Joseph C. Chan, M.D., and Grace Kelly, R.N.; Case Western Reserve University — Charles J. Fisher, Jr., M.D. (principal investigator), Edward A. Panacek, M.D., William F. Rutherford, M.D., Bruce Sherman, M.D., and Mark Munger, Pharm.D.; University of California Davis Medical Center — Garrett E. Foulke, M.D. (principal investigator), Timothy E. Albertson, M.D., Ph.D., Karen Mondragon, R.N., and Dorothy J. Harlow, R.N.; University of Massachusetts — Mitchell Fink, M.D. (principal investigator), Cathleen M. Helsmoortel, R.N., Stephen O. Heard, M.D.; Stephen M. Cohn, M.D., Donna A. Soja, R.N., and Laurence Landow, M.D.; Academic Medical Center, Amsterdam — Cornelis H. Wortel, M.D., Maarten J. Lubbers, M.D., Hans G. Schipper, M.D., and Jan W. ten Cate, M.D. (principal investigator); Baylor College of Medicine — R. Phillip Dellinger, M.D. (principal investigator), and Janice Zimmerman, M.D.; University of Pennsylvania — Paul Lanken, M.D. (principal investigator), and Harvey Rubin, M.D.; State University of New York, Syracuse — Michael Jastremski, M.D. (principal investigator), Jonathan Warren, M.D., and Leo Rotello, M.D.; University of Washington — Richard Maunder, M.D. (principal investigator), E. Patchen Dellinger, M.D., Margaret J. Wertz, R.N., M.N., and Sandra Hart, R.N.; University of Florida, Gainesville — T. James Gallagher, M.D. (principal investigator). Edward K. McGough, M.D., Eran Moshe Segal, M.D., and Kenneth Reese Courington, M.D.; University of Michigan — Robert Fekety, M.D. (principal investigator), Michael H. Otto, M.D., and Dayamal Waas, M.D.; University of Winnipeg — Bruce Light, M.D. (principal investigator), Daniel E. Roberts, M.D., Patricia Ostryzniuk, R.N., and Ailsa Shanks, R.N.; State University of New York, Buffalo — David E. Nix, Pharm.D., and Thomas Cumbo, M.D. (principal investigators), and Jerome J. Schentag, Pharm.D.; San Diego Consortium — Elizabeth J. Ziegler, M.D. (principal investigator), and Annette Wunderlich, B.A. (University of California Medical Center), Stanley Amundsen, M.D. (Mercy Hospital and Medical Center), and Joshua Fierer, M.D. (San Diego Veterans Affairs Hospital); Saint Elizabeth Hospital, Youngstown, Ohio — Lawrence Woods, D.O. (principal investigator), Alan Cropp, D.O., and Peter Venziano, M.D.; Saint Thomas Hospital, Nashville — Raymond Fletcher, M.D., Ph.D. (principal investigator); Massachusetts General Hospital, Boston — Warren Zapol, M.D. (principal investigator), and Karen Lynch, R.N.; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland — Michael Glauser, M.D. (principal investigator); Southern Connecticut Research Foundation — John L. Ryan, M.D., Ph.D. (principal investigator) (West Haven Veterans Affairs Medical Center), Richard J. Mangi, M.D. (Saint Raphael Hospital), George Thornton, M.D. (Waterbury Hospital), and Thomas P. Greco, M.D. (Saint Mary's Hospital); Military Consortium — Jerald C. Sadoff, M.D. (principal investigator) (Walter Reed Army Institute of Research), Joel D. Brown, M.D. (Tripler Army Medical Center), James D. Bales, M.D. (Fitzsimmons Army Medical Center), Gregory Melcher, M.D. (Wilford Hall U.S. Air Force Medical Center), Joseph P. Ducey, M.D. (Brooke Army Medical Center), and Arn Eliasson, M.D. (Walter Reed Army Medical Center); Stanford University — Thomas W. Feeley, M.D. (principal investigator), and Nelson N.H. Teng, M.D., Ph.D.; University of Colorado Health Sciences Center — Joseph Marr, M.D. (principal investigator); Middlesex Hospital, London — Catherine Bullen, M.D. (principal investigator); and Victoria Hospital Corp., London, Ont. — William J. Sibbald, M.D. (principal investigator). Centocor Research and Development: I. Elaine Allen, Ph.D., Harvey J. Berger, M.D., Corazon Dating, Ph.D., Charles Kilgarriff, B.S., Craig R. Smith, M.D., and Richard C. Straube, M.D. Clinical Evaluation Committee: Charles J. Fisher, Jr., M.D., Jerald C. Sadoff, M.D., Charles L. Sprung, M.D., Elizabeth J. Ziegler, M.D., Richard C. Straube, M.D. (ex officio) and Craig R. Smith, M.D. (ex officio). Coordinating Center (Maryland Medical Research Institute): Sandra Forman, M.A., Genell Knatterud, Ph.D., Michael Terrin, M.D., and Bruce Thompson, Ph.D. Core Laboratory (University of Alabama, Birmingham): Albert F. LoBuglio, M.D., and M.B. Khazaeli, Ph.D. Safety and Efficacy Monitoring Committee: Rev. Canon Michael Hamilton (Washington Cathedral), Richard Hornick, M.D. (Orlando, Fla., Regional Medical Center), Richard Matthay, M.D. (Yale University), George Santos, M.D. (Johns Hopkins University), Janet Wittes, Ph.D. (National Heart, Lung, and Blood Institute), and Genell Knatterud, Ph.D. (ex officio). Publication Committee: Charles J. Fisher, Jr., M.D., Jerald C. Sadoff, M.D., Craig R. Smith, M.D., Charles L. Sprung, M.D., Richard C. Straube, M.D., and Elizabeth J. Ziegler, M.D. species and contains lipid A, thought to be the toxic moiety of endotoxin.
Polyclonal J5 antiserum is not commercially available for several reasons. Vaccinating serum donors with J5 vaccine is associated with mild toxicity; there is no booster response, so a person can donate only once; the antibody content of antiserum preparations varies; and there is the potential for transmitting infection with pooled human blood. The use of monoclonal-antibody techniques circumvents these problems and allows the production of large quantities of antibody of known isotype and epitope specificity. Furthermore, a human monoclonal antibody offers the potential advantage of better effector function than antibodies from other species.
HA-1A (Centoxin) is a human monoclonal IgM antibody that binds to the lipid A domain of endotoxin and is produced by the stable heteromyeloma cell line A6(H4C5) developed by Teng, Kaplan, and Braude.9 The same heat-inactivated E. coli J5 vaccine that induced polyclonal J5 antiserum was used in the development of this cell line. HA-1A has been shown to bind specifically to many endotoxins and to a broad range of clinical isolates of gram-negative bacteria. In various animal models of gram-negative bacteremia and endotoxemia, the administration of HA-1A after challenge prevents the development of the dermal Shwartzman reaction and death.9 , 10
To determine the efficacy of HA-1A in reducing the mortality associated with gram-negative bacteremia, we conducted a prospective, muhicenter, randomized, double-blind, placebo-controlled clinical trial in patients with the sepsis syndrome and a presumptive diagnosis of gram-negative infection.
Methods
The efficacy and safety of HA-1A were assessed in a double-blind fashion and analyzed according to a prospectively developed plan that used definitions adopted before the treatment-allocation code was broken. The analysis focused on the patients with gram-negative bacteremia because this group had proved gram-negative infection with a high likelihood of endotoxemia,5 , 6 but all treated patients were analyzed.
An independent coordinating center (Maryland Medical Research Institute, Baltimore) was responsible for creating a treatment-allocation code for each site, labeling vials, monitoring compliance with the blinding procedures, auditing the data for consistency and accuracy, and conducting the interim analyses. The coordinating center appointed a Safety and Efficacy Monitoring Committee to oversee the trial, which was undertaken at 24 academic medical centers in the United States, Canada, and Europe. The protocol was approved by the institutional review board at each hospital, and informed consent was obtained from all participants.
Patient Selection
Patients with sepsis and suspected gram-negative infection were enrolled in this clinical trial by their physicians and randomly assigned to receive HA-1A or placebo. The criteria for a diagnosis of sepsis were as follows: fever or hypothermia (temperature >38.3°C [101°F] or <35.6°C [96°F]); tachycardia (>90 beats per minute in the absence of beta-blockade) and tachypnea (respiratory rate >20 breaths per minute or the requirement of mechanical ventilation); and either hypotension (systolic blood pressure ≤90 mm Hg or a sustained drop in systolic pressure ≥40 mm Hg in the presence of an adequate fluid challenge and the absence of antihypertensive agents) or two of the following six signs of systemic toxicity or peripheral hypoperfusion: unexplained metabolic acidosis (pH ≤7.3, base deficit of >5 mmol per liter, or an elevated plasma lactate level); arterial hypoxemia (partial pressure of oxygen ≤75 mm Hg or ratio of the partial pressure of oxygen to the fraction of inspired oxygen <250); acute renal failure (urinary output of less than 0.5 ml per kilogram of body weight per hour); elevated prothrombin or partial-thromboplastin time or reduction of the platelet count to less than half the base-line value or less than 100,000 platelets per cubic millimeter; sudden decrease in mental acuity; and cardiac index of more than 4 liters per minute per square meter of body-surface area with systemic vascular resistance of less than 800 dyn · sec · cm-5.
Patients were not eligible for the trial if they were less than 18 years of age; if pregnancy was suspected; if their condition was clearly irreversible, with a rapidly fatal course; if they had undergone organ transplantation; if uncontrolled hemorrhage, cardiogenic shock, or burn injury was the primary acute underlying condition, or if they had been given any monoclonal antibodies or intravenous immunoglobulins (except fresh-frozen plasma) within 21 days.
Treatment
HA-1A is produced by continuous-perfusion cell culture and is purified from the supernatant fluid by a series of steps involving selective precipitation and column chromatography. The cell line that produces HA-1A has been tested extensively and has been shown to be free of human viruses. Furthermore, the purification process for HA-1A includes specific viral-inactivation procedures, and tests are performed to confirm the absence of viruses. None of the lots contained detectable endotoxin in an assay with a sensitivity of 3 pg per milliliter.
Patients enrolled in the trial were randomly assigned to receive either 100 mg of HA-1A diluted with 3.5 g of human serum albumin or a placebo consisting of 3.5 g of human serum albumin. The contents of each vial were diluted to a final volume of 50 ml and given in a single intravenous infusion over a period of 15 to 20 minutes.
Decisions regarding the use of antibiotics, intravenous fluids, cardiovascular and respiratory support, and surgical intervention were made by each patient's attending physicians and were not dictated by the study protocol.
Evaluation of the Patients
Patients were followed for 28 days or until death. An APACHE II score, a severity-of-illness index,11 was calculated at entry. Samples of blood and all other suspected foci of infection were obtained for culture within the 24 hours before enrollment. Vital signs (blood pressure, temperature, heart rate, and respiratory rate) were recorded frequently during the first 12 hours after the infusion of HA-1A or placebo and then on days 1, 2, 3, 5, 7, 14, and 28. Routine hematologic and clinical chemistry tests were obtained before infusion, 12 hours after infusion, and daily thereafter until the values were normal.
Serum for the determination of anti—HA-lA antibody levels was obtained before and approximately 28 days after infusion. Serum was assayed for anti—HA-1A antibodies at the core laboratory with a double-antigen radiometric assay similar to that described previously.12 The sensitivity of the assay was 0.35 μg of antibody per 0.1 ml of serum.
Definitions and Criteria
To minimize site-to-site variation in the classification of patients, a four-member Clinical Evaluation Committee was organized, as dictated by the study protocol. The committee established the definitions used in the trial and classified each case with respect to underlying disease, culture status, primary site of infection, causative organism, adequacy of antibiotic therapy, and adequacy of surgery. Each case was classified by one infectious-disease specialist and one critical care specialist. Committee members did not examine cases from their own centers. All the work of the committee was completed in a blinded fashion before the treatment-allocation code was broken.
In the study, the term "sepsis" was defined by the inclusion criteria. This definition is similar to that proposed by Bone and colleagues.13 Shock was defined as a systolic blood pressure of less than 90 mm Hg or the use of vasopressor drugs to maintain blood pressure. Gram-negative bacteremia was defined as the isolation of pathogenic gram-negative bacteria from at least one blood culture. We defined the adult respiratory distress syndrome using a modification of the criteria of Murray et al.,14 requiring a total score of more than 7.5 based on points assigned for chest radiographic findings, amount of positive end-expiratory pressure required, and degree of hypoxemia. Renal failure was defined as a serum creatinine level of 177 μmol per liter (2 mg per deciliter) or more, or the need for dialysis. Hepatic failure was defined as the presence of two of the following: a total bilirubin level higher than 43 μmol per liter (2.5 mg per deciliter); aspartate aminotransferase or alanine aminotransferase levels more than twice the normal laboratory value; and a prothrombin time at least 1.5 times the normal value or a partial-thromboplastin time at least 1.2 times the normal value. Renal and hepatic failure were defined as acute if they had not been present before the development of sepsis. Disseminated intravascular coagulation was defined as both a platelet count of less than 100,000 cells per cubic millimeter (or a decrease of more than 50 percent from a previously measured value) and a prothrombin time at least 1.5 times the normal value or a partial-thromboplastin time at least 1.2 times the normal value. If coagulation abnormalities qualified a case as one of disseminated intravascular coagulation, they were not used for the classification of hepatic failure.
Antibiotic treatment was considered adequate if within one day of infusion of the study material the patient received an antibiotic to which each isolated organism was sensitive. Patients with pseudomonas infection of the respiratory tract needed either two classes of antibiotics or imipenem or a third-generation cephalosporin to which the organism was susceptible. Patients with ruptured bowel needed appropriate antibiotic coverage for enteric facultative and anaerobic gram-negative bacteria, including Bacteroides fragilis.
Statistical Analysis
The sample size was calculated to detect a 50 percent reduction in mortality among patients with gram-negative bacteremia at day 14, the midpoint between treatment and the end of follow-up. For the calculation we assumed a mortality of 30 percent in the placebo group, an expected incidence of gram-negative bacteremia of 40 percent in patients with sepsis, an alpha error of 0.05, and a beta error of 0.2.
For the trial we used the Harrington modification of the O'Brien-Fleming group sequential boundaries,15 with two interim analyses conducted by the coordinating center. The results of each analysis were provided to the independent Safety and Efficacy Monitoring Committee. All others were blinded to these interim results.
Groups were compared by Student's t-test or the Wilcoxon rank-sum test for continuous variables and chi-square tests for categorical variables. All tests of significance were two-tailed. To analyze the difference in mortality over the 28-day period after therapy, Kaplan–Meier survival curves were constructed for the two study groups and compared by the Wilcoxon statistic. In a further analysis, patients were stratified according to each strong prognostic factor, and the Cochran—MantelHaenszel statistic was used to test whether the treatment effect of HA-1A remained significant after adjustment for the distribution of prognostic factors in the two study groups. A Cox proportional-hazards model was used to control for the influence of pretreatment shock and the APACHE II score on the treatment effect of HA-1A. Because a group sequential method of analysis was used, a P value of less than 0.049 was considered significant.
Results
There were 543 patients (262 HA-1A recipients and 281 placebo recipients) in the trial, of whom 200 (37 percent) proved to have had gram-negative bacteremia according to cultures of blood drawn before enrollment. The analysis of efficacy of HA-1A in this report is based on these 200 patients with gram-negative bacteremia. Information was available on all of them through day 14 and on 197 (99 percent) through day 28. The three patients who were lost to follow-up, all in the placebo group, were discharged from the hospital.
Comparisons between Study Groups
Among the patients with gram-negative bacteremia, 105 received HA-1A and 95 received placebo. The treatment and placebo groups were well balanced with respect to demographic characteristics and underlying diseases (Table 1Table 1
Demographic Characteristics of the Patients with Gram-Negative Bacteremia.*), the distribution of anatomical sources of bacteremia (Table 2Table 2
Sources of Gram-Negative Bacteremia.*), and causative organisms (Table 3Table 3
Blood Isolates in Patients with Gram-Negative Bacteremia.*). As shown in Table 4, the patients with gram-negative bacteremia were severely ill when they entered the study. The median intervals between the diagnosis of sepsis and infusion of the study drug were 9.3 hours in the placebo group and 14.3 hours in the HA-1A group. The temporal relation between the diagnosis of sepsis and the administration of adequate antibiotics was similar in the two groups (P = 0.43). Antibiotic treatment was judged to be adequate in 87 percent of the placebo recipients and 93 percent of those who received HA-1A. More than one adequate antibiotic was administered to 63 of the 95 placebo recipients (66 percent) and to 56 of the 105 recipients of HA-1A (53 percent). These differences between study groups were not significant. The use of corticosteroids, nonsteroidal antiinflammatory drugs, and narcotic antagonists was also well balanced (27 and 26 percent, 5 and 6 percent, and 6 and 5 percent, respectively). Surgical therapy for infection was judged adequate in 96 percent of those in the placebo group and 94 percent of those in the HA-1A group.Efficacy of HA-1A in Gram-Negative Bacteremia
HA-1A significantly reduced mortality by 39 percent in the 200 patients with sepsis and gram-negative bacteremia. By 28 days after infusion there were 45 deaths among the 92 placebo recipients still being followed (49 percent) and 32 deaths among the 105 recipients of HA-1A (30 percent). The Kaplan–Meier survival curves for this population (Fig. 1Figure 1
Probability of Survival in Patients with Gram-Negative Bacteremia.) show that the reduction in mortality was evident as early as the first day after treatment, was sustained throughout the entire 28-day period of evaluation, and was significant (P = 0.014).When mortality was examined in the patients with gram-negative bacteremia who were in shock before the infusion, a 42 percent reduction was observed. The number of deaths after 28 days was 27 of 47 patients (57 percent) in the placebo group and 18 of 54 patients (33 percent) in the HA-1A group (P = 0.017). The Kaplan–Meier survival curves for this population are shown in Figure 2Figure 2
Probability of Survival in Patients with Gram-Negative Bacteremia and Shock at Entry.. In the patients who were not in shock before infusion, the number of deaths by day 28 was 18 of 45 (40 percent) in the placebo group and 14 of 51 (27 percent) in the HA-1A group, a 33 percent reduction. A Cox proportional-hazards model was fitted to the survival data with treatment and shock as independent variables. This analysis indicated that shock was an important determinant of survival (P = 0.047) and that HA-1A reduced mortality in both patients with shock and patients without shock (P = 0.012).Pretreatment APACHE II scores were highly correlated with death among the patients given placebo in all populations examined (P = 0.0001). In order to determine whether severely ill and less severely ill patients benefited from HA-1A, the patients with gram-negative bacteremia were divided into two groups according to whether their APACHE II scores were >25 or ≤25, the median value for the population. We fitted a Cox proportional-hazards model using treatment group and APACHE II score as the independent variables (Fig. 3Figure 3
Days after Infusion). This analysis showed a significant reduction in mortality among both severely ill and less severely ill patients who received HA-1A (P = 0.017).To examine more fully the independence of the treatment effect of HA-1A in gram-negative bacteremia, we used the Cochran—MantelHaenszel statistic for the following factors that might influence mortality: age, site of infection, category of underlying disease, neutropenia, pretreatment platelet count < 100,000 per cubic millimeter, pretreatment arterial hypoxemia (ratio of partial pressure of arterial oxygen to fraction of inspired oxygen, <250), pseudomonas infection, adequacy of antibiotic therapy, and adequacy of surgery for infection. These variables have previously been associated with mortality in gram-negative bacteremia or were shown in this trial to be related to a fatal outcome in the placebo group. The treatment effect of HA-1A in patients with gram-negative bacteremia remained significant after we adjusted for each of these variables.
One or more of the major complications of sepsis—shock, disseminated intravascular coagulation, acute renal failure, acute hepatic failure, or the adult respiratory distress syndrome — were present at the time of infusion in 123 of the 200 patients with gram-negative bacteremia. During the first seven days after treatment, all evidence of these complicating conditions resolved in 26 of 62 patients given placebo (42 percent) and in 38 of 61 patients given HA-1A (62 percent; P = 0.024).
In order to evaluate the effectiveness of HA-1A further, the hospital records of all the patients who remained hospitalized 28 days after infusion were reviewed to determine survival status at discharge. At the time of the record review, 198 of the 200 patients had died or been discharged alive. Hospital records were available for 196 of these 198 patients (99 percent). The number of patients discharged alive was 45 of 93 (48 percent) in the placebo group and 65 of 103 (63 percent) in the HA-1A group (P = 0.038).
We analyzed the groups of patients who did not have gram-negative bacteremia to determine the specificity of protection by HA-1A. There was no significant difference in mortality between study groups among the 201 patients with nonbacteremic gram-negative infection (P = 0.30), the 51 patients with gram-positive infection without gram-negative infection (P = 0.15), the 7 patients with fungal infection (P = 0.14 by Fisher's exact test), the 84 patients with no infection identified (P = 0.96), or the entire population of 343 patients without gram-negative bacteremia (P = 0.68). When the results in patients without gram-negative bacteremia were combined with the results in those with the condition, the 28-day mortality rate in all the patients who received infusions (excluding 5 placebo recipients and 7 recipients of HA-1A lost to follow-up after discharge between day 3 and day 28) was 118 of 276 (43 percent) among placebo recipients and 100 of 255 (39 percent) among recipients of HA-1A (P = 0.24).
Safety
The incidence of adverse events, including serial changes in vital signs and laboratory measurements, was not significantly different in the HA-1A and placebo groups. There were no serious adverse reactions in the 291 patients given HA-1A. One patient had a transient episode of localized hives near the site of HA-1A infusion 10 to 15 minutes after the infusion, and it resolved without therapy. Near the end of the infusion, another HA-1A recipient had facial flushing and mild hypotension, which resolved without therapy in 30 minutes. Serum samples for assay of human antibody directed against HA-1A were obtained from 252 patients, 116 of whom had been given HA-1A. No patient had detectable anti—HA-lA antibodies.
Discussion
The results of this clinical trial show that adjunctive therapy with HA-1A, a human monoclonal antibody against endotoxin, reduces mortality significantly in patients with sepsis and gram-negative bacteremia. The reduction in mortality was apparent as early as day 1 after treatment and was sustained throughout the 28 days of observation. The treatment effect of HA-1A was strong and remained significant after adjustment for factors usually associated with a poor outcome. Both patients with a poor prognosis and those with a better prognosis, as defined by either the APACHE II score or the presence or absence of shock at the time of treatment, benefited from HA-1A therapy. HA-1A treatment was also associated with more rapid resolution of the major complications of sepsis than was placebo, and with a significantly higher rate of survival at hospital discharge.
The results of this clinical trial are similar to the results of a previous clinical trial of human polyclonal J5 antiserum, in which mortality in patients with gram-negative bacteremia was reduced by 37 percent and in patients with septic shock by 39 percent.7 Comparable reductions of 39 and 42 percent were observed with HA-1A in the present trial. These two studies provide convincing evidence that immunotherapy with human antibody directed against a determinant expressed by the J5 mutant of E. coli confers substantial therapeutic benefit in patients with gram-negative bacteremia, including those with septic shock.
A concurrent control group was essential in this trial, since the mortality rate in gram-negative bacteremia is variable.3 We decided that the trial of most value would be one that determined whether adding HA-1A to conventional therapy would improve survival in patients with sepsis and a presumptive diagnosis of gram-negative bacteremia. Human serum albumin was used because it is a safe, commercially available inactive control for the albumin used as an excipient in the HA-1A preparation. Other possible controls, such as human IgM, J5 polyclonal antiserum, and unrelated monoclonal antibodies, are experimental drugs, and their use would not have allowed extrapolation of the results to clinical practice.
Polyclonal J5 antiserum contains antibodies to both strain-specific and shared determinants of endotoxin from the J5 mutant. The shared determinants include lipid A, which is the most likely region to stimulate cross-reactive antibodies, because its structure is so highly conserved among gram-negative bacterial species.16 Another bacterial mutant, the Salmonella minnesota Re strain, contains endotoxin consisting only of lipid A and one sugar. Human polyclonal IgM generated against this mutant protected animals from lethal challenge with several different gram-negative bacteria.17 The human monoclonal IgM of Teng et al. exhibits similar cross-reactivity with a wide variety of heterologous gram-negative bacteria and their endotoxins, including the J5 and Re mutants.9 HA-1A, the antibody purified from this cell line by Centocor, behaves identically in vitro. Both the monoclonal supernatant fluid of Teng et al. and HA-1A protect rabbits with established pseudomonas bacteremia against death in a model in which J5 polyclonal antiserum was also shown to be effective.10 HA-1A binds to lipid A and its analogues in enzyme-linked immunosorbent assays and in thin-layer chromatography, and the binding can be inhibited by the previous incubation of HA-1A with lipid A, monophosphoryl lipid A, polymyxin B, or a well-characterized murine IgGl against lipid A, but not by incubation with an irrelevant IgGl9 , 18 (and Ziegler EJ: unpublished data). Taken together, these data suggest that cross-protective IgM antiendotoxin antibodies are directed against an epitope on lipid A.
Some investigators have reported negative results with antiendotoxin core antiserum. Most of their studies were performed in mice. Although the reasons for discrepant results are not fully understood, several factors may contribute.17 , 19 These include the relative resistance of rodents to endotoxin, the need to compromise host defenses severely in order to establish satisfactory animal models of gram-negative infection and endotoxemia, and the rather low affinity of cross-reactive antiendotoxin core antibodies as compared with type-specific antibodies. Recently, Baumgartner et al.20 reported a lack of protection by a human monoclonal antibody derived from cells isolated from the same original clone as HA-1A, but the antibody was not produced or purified by the laboratory that produced HA-1A. Whether the discrepancies between their results and ours are due to differences in the monoclonal-antibody preparations or to the factors discussed above is not known. When species resembling humans in endotoxin sensitivity are studied, protection from J5 antibody can be demonstrated.21 The negative results of Calandra et al. with J5 immunoglobulin in patients with gram-negative septic shock22 may have been due to the absence of IgM in their preparation.
HA-1A has been administered in phase I trials to 15 patients with cancer23 and in unblinded fashion to 34 patients with sepsis,24 as well as to the 291 patients who received it in the present trial. In all these patients HA-1A was safe, well tolerated, and nonimmunogenic.
The treatment effect of HA-1A in this trial was specific for patients with sepsis and gram-negative bacteremia. Patients with gram-negative bacteremia frequently have endotoxemia.5 Since HA-1A is an IgM antibody to endotoxin, it should be particularly effective against endotoxin in the bloodstream. The specificity of the HA-1A treatment effect for patients with gram-negative bacteremia supports the hypothesis that HA-1A protects patients by blocking the toxic effects of circulating endotoxin, which include induction and release of the mediators of shock and tissue damage. The pathogenesis of the sepsis syndrome in patients without gram-negative bacteremia presumably involves the release of mediators of sepsis through mechanisms that do not require endotoxin or by pathways in which endotoxin participates outside the bloodstream, in locations inaccessible to circulating HA-1A.
Sepsis requires prompt treatment, since the patient's condition often deteriorates rapidly, before the results of blood cultures are known. Therefore, in view of the lifesaving benefit of HA-1A in gram-negative bacteremia and the minimal risk associated with the administration of the antibody, empirical immunotherapy with HA-1A should be considered when patients with suspected gram-negative infection present with sepsis. The patients enrolled in this trial were severely ill and met specific criteria for the diagnosis of gram-negative sepsis. These criteria appear to identify patients with a 30 to 40 percent probability of having gram-negative bacteremia. The results of this trial should not be extended to infected patients who are not sick enough to meet our criteria for sepsis but should be applied only to patients with sepsis and presumed gram-negative bacteremia. Larger trials will be needed to determine whether HA-1A benefits patients with sepsis and focal gram-negative infections without bacteremia. Our results indicate that HA-1A is safe and that it substantially reduces mortality in patients with sepsis and gram-negative bacteremia. These findings illustrate the potential of human monoclonal immunotherapy in clinical medicine.
Supported by Centocor, Inc.
Drs. Ziegler, Teng, and LoBuglio were consultants to Centocor (the manufacturer of HA-1A) during the course of the trial.
*Members of the HA-1A Sepsis Study Group are listed at the bottom of the next page.
Source Information
From the Department of Medicine, University of California San Diego, San Diego (E.J.Z.); the Department of Medicine, Case Western Reserve University, Cleveland (C.J.F.); the Department of Medicine, University of Miami, Miami (C.L.S.); the Research and Development Division, Centocor, Inc., Malvern, Pa. (R.C.S., I.E.A., H.J.B., C.R.S.); the Department of Bacterial Diseases, Walter Reed Army Institute of Research, Washington, D.C. (J.C.S.); the Department of Medicine, University of California Davis, Sacramento (G.E.F.); the Center for Hemostasis, Thrombosis, and Atherosclerosis Research and the Department of Intensive Care, Academic Medical Center, University of Amsterdam, Amsterdam (C.H.W.); the Department of Surgery, University of Massachusetts, Worcester (M.P.F.); the Department of Medicine, Baylor College of Medicine, Houston (R.P.D.); the Department of Obstetrics and Gynecology and the Cancer, Biology Research Laboratory, Stanford University, Stanford, Calif. (N.N.H.T.); Maryland Medical Research Institute, Baltimore (G.L.K.); and the Department of Medicine, University of Alabama, Birmingham (A.F.L.). Address reprint requests to Dr. Fisher at the Center for Critical Care Research, Div. of Pulmonary and Critical Care Medicine, University Hospitals of Cleveland, 2074 Abington Rd., Cleveland, OH 44106.
- References
References
1
Increase in national hospital discharge survey rates for septicemia — United States, 1979–1987 . MMWR 1990; 39:31–4.
Medline2
Bone
Full Text | Web of Science | Medline3
Kreger
CrossRef | Web of Science | Medline4
The Veterans Administration Systemic Sepsis Cooperative Study Group
Full Text | Web of Science | Medline5
Stumacher
Full Text | Web of Science | Medline6
van Deventer
CrossRef | Web of Science | Medline7
Ziegler
Full Text | Web of Science | Medline8
Baumgartner
CrossRef | Web of Science | Medline9
Teng
CrossRef | Web of Science | Medline10
Ziegler 11
Knaus
CrossRef | Web of Science | Medline12
LoBuglio
CrossRef | Web of Science | Medline13
Bone
CrossRef | Web of Science | Medline14
Murray
Web of Science | MedlineErratum, Am Rev Respir Dis 1989; 139:1065.
15
Fleming
CrossRef | Medline16
Rietschel
CrossRef | Medline17
McCabe
CrossRef | Web of Science | Medline18
Bogard WC Jr, Damiano EM, Leone AO, Kaplan P, Siegel SA. The human monoclonal antibody HA-1A binds to endotoxin via epitopes in the lipid A domain of lipopolysaccharide (LPA). Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, October 21–24, 1990.
19
Ziegler
CrossRef | Web of Science | Medline20
Baumgartner
CrossRef | Web of Science | Medline21
Spier
Medline22
Calandra
CrossRef | Web of Science | Medline23
Khazaeli
Medline24
Fisher
CrossRef | Web of Science | Medline
- Citing Articles (341)
Citing Articles
1
Claire Jones, Stephen A. Badger, James M. Black, Neil V. McFerran, Margaret Hoper, Tom Diamond, Rowan W. Parks, Mark A. Taylor. (2012) The use of antiendotoxin peptides in obstructive jaundice endotoxemia. European Journal of Gastroenterology & Hepatology1
CrossRef2
Wolfram Hoetzenecker, Bernd Echtenacher, Emmanuella Guenova, Konrad Hoetzenecker, Florian Woelbing, Jürgen Brück, Anna Teske, Nadejda Valtcheva, Kerstin Fuchs, Manfred Kneilling, Ji-Hyeon Park, Kyu-Han Kim, Kyu-Won Kim, Petra Hoffmann, Claus Krenn, Tsonwin Hai, Kamran Ghoreschi, Tilo Biedermann, Martin Röcken. (2011) ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immunosuppression. Nature Medicine
CrossRef3
Byungse Suh, Rafik Samuel. 2011. Drotrecogin Alfa Activated (Recombinant Human Activated Protein C, Xigris). .
CrossRef4
Vivek Kak. (2011) Mediators of Systemic Inflammatory Response Syndrome and the Role of Recombinant Activated Protein C in Sepsis Syndrome. Infectious Disease Clinics of North America 25:4, 835-850
CrossRef5
Mark W. Julian, Shengying Bao, Daren L. Knoell, Ruairi J. Fahy, Guohong Shao, Elliott D. Crouser. (2011) Intestinal epithelium is more susceptible to cytopathic injury and altered permeability than the lung epithelium in the context of acute sepsis. International Journal of Experimental Pathology 92:5, 366-376
CrossRef6
Palle Toft, Else Tønnesen. (2011) Immune-modulating interventions in critically ill septic patients: pharmacological options. Expert Review of Clinical Pharmacology 4:4, 491-501
CrossRef7
Koichi Sato, Hiroshi Maekawa, Mutsumi Sakurada, Hajime Orita, Yoshihiro Komatsu. (2011) Direct hemoperfusion with polymyxin B immobilized fiber for abdominal sepsis in Europe. Surgery Today 41:6, 754-760
CrossRef8
Mark Tidswell, Steven P LaRosa. (2011) Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis. Expert Review of Anti-infective Therapy 9:5, 507-520
CrossRef9
G. Novelli, V. Morabito, F. Pugliese, G. Ferretti, S. Novelli, S. Ianni, Q. Lai, M. Rossi, P.B. Berloco. (2011) Management of Sepsis During MARS Treatment in Acute on Chronic Liver Failure. Transplantation Proceedings 43:4, 1085-1090
CrossRef10
2011. References. , 193-223.
CrossRef11
Amisha Barochia, Steven Solomon, Xizhong Cui, Charles Natanson, Peter Q Eichacker. (2011) Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opinion on Drug Metabolism & Toxicology 7:4, 479-494
CrossRef12
Lien Dejager, Iris Pinheiro, Eline Dejonckheere, Claude Libert. (2011) Cecal ligation and puncture: the gold standard model for polymicrobial sepsis?. Trends in Microbiology 19:4, 198-208
CrossRef13
Deborah J. Stearns-Kurosawa, Marcin F. Osuchowski, Catherine Valentine, Shinichiro Kurosawa, Daniel G. Remick. (2011) The Pathogenesis of Sepsis. Annual Review of Pathology: Mechanisms of Disease 6:1, 19-48
CrossRef14
D. R. Goldhill, C. S. Waldmann. (2011) Evidence-based critical care medicine: seeing through a glass darkly. Anaesthesia 66:2, 75-80
CrossRef15
Mingxin Li, Jun Xue, Junfeng Liu, Dingwei Kuang, Yong Gu, Shanyan Lin. (2011) Efficacy of Cytokine Removal by Plasmadiafiltration Using a Selective Plasma Separator: In Vitro Sepsis Model. Therapeutic Apheresis and Dialysis 15:1, 98-108
CrossRef16
D. Spoerl, Andreas J. Bircher. 2011. Drugs that act on the immune system. , 769-814.
CrossRef17
Aaron L. Nelson, Eugen Dhimolea, Janice M. Reichert. (2010) Development trends for human monoclonal antibody therapeutics. Nature Reviews Drug Discovery 9:10, 767-774
CrossRef18
Errol R. Norwitz, Hee Joong Lee. 2010. Septic Shock. , 571-595.
CrossRef19
Takahiro Hijiya, Yasuko Shibata, Mitsuo Hayakawa, Yoshimitsu Abiko. (2010) A Monoclonal Antibody Against FimA Type II Porphyromonas gingivalis Inhibits IL-8 Production in Human Gingival Fibroblasts. Hybridoma 29:3, 201-204
CrossRef20
Zhang Peng, Peng Pai, Liu Hong-Bao, Li Rong, Wang Han-Min, Huang Chen. (2010) The impacts of continuous veno-venous hemofiltration on plasma cytokines and monocyte human leukocyte antigen-DR expression in septic patients. Cytokine 50:2, 186-191
CrossRef21
J. C. Hurley. (2010) Does gram-negative bacteraemia occur without endotoxaemia? A meta-analysis using hierarchical summary ROC curves. European Journal of Clinical Microbiology & Infectious Diseases 29:2, 207-215
CrossRef22
Shigeki Kushimoto, Hiroyuki Yokota, Masato Miyauchi, Makoto Kawai, Atsuko Tsujii, Shiei Kim. (2010) How to comprehend the pathophysiology of sepsis and treat the patients with endotoxemia?. Nihon Kyukyu Igakukai Zasshi 21:3, 101-117
CrossRef23
Sang-Min Lee, Yeon Sil Jang, Choon-Taek Lee, Young Whan Kim, Sung Koo Han, Young-Soo Shim, Chul-Gyu Yoo. (2010) Role of Insulin in the Activation of NF-κB/IκB Pathway in Macrophage Cells. Tuberculosis and Respiratory Diseases 68:3, 168
CrossRef24
Mark Tidswell, William Tillis, Steven P. LaRosa, Melvyn Lynn, Alec E. Wittek, Richard Kao, Janice Wheeler, Jagadish Gogate, Steven M. Opal. (2010) Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*. Critical Care Medicine 38:1, 72-83
CrossRef25
Mitsuhiro Maruyama, Mitsuo Hayakawa, Lin Zhang, Yasuko Shibata, Yoshimitsu Abiko. (2009) Monoclonal Antibodies Produced Against Lipopolysaccharide from fimA Type II Porphyromonas gingivalis. Hybridoma 28:6, 431-434
CrossRef26
Hidehiko Kushi, Takahiro Miki, Yuichiro Sakagami, Jun Sato, Takeshi Saito, Katsuhisa Tanjoh. (2009) Hemoperfusion With an Immobilized PolymyxinâB Fiber Column Decreases Macrophage and Monocyte Activity. Therapeutic Apheresis and Dialysis 13:6, 515-519
CrossRef27
Thierry Gustot, François Durand, Didier Lebrec, Jean-Louis Vincent, Richard Moreau. (2009) Severe sepsis in cirrhosis. Hepatology 50:6, 2022-2033
CrossRef28
Suzanne Heemskerk, Rosalinde Masereeuw, Frans G. M. Russel, Peter Pickkers. (2009) Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injury. Nature Reviews Nephrology 5:11, 629-640
CrossRef29
Haichao Wang, Mary F. Ward, Andrew E. Sama. (2009) NOVEL HMGB1-INHIBITING THERAPEUTIC AGENTS FOR EXPERIMENTAL SEPSIS. Shock 32:4, 348-357
CrossRef30
Oddeke van Ruler, Marcus J. Schultz, Johannes B. Reitsma, Dirk J. Gouma, Marja A. Boermeester. (2009) Has Mortality from Sepsis Improved and What to Expect from New Treatment Modalities: Review of Current Insights. Surgical Infections 10:4, 339-348
CrossRef31
Brent R. Weil, Troy A. Markel, Jeremy L. Herrmann, Aaron M. Abarbanell, Megan L. Kelly, Daniel R. Meldrum. (2009) Stem Cells in Sepsis. Annals of Surgery 250:1, 19-27
CrossRef32
Lara Vivienne Marks. (2009) Collaboration – a competitor's tool: The story of Centocor, an entrepreneurial biotechnology company. Business History 51:4, 529-546
CrossRef33
P. Guillot-Chene, S. Lebecque, D. Rigal. (2009) Vers une maîtrise industrielle du clonage des lymphocytes B humains pour la fabrication des anticorps monoclonaux issus du répertoire humain. Annales Pharmaceutiques Françaises 67:3, 182-186
CrossRef34
Xiao-Tao Jiang, Bei-Yi Liu, Ping Zhu, Ning Fu. (2009) Production and Characterization of a Cross-Reactive Monoclonal Antibody to Lipopolysaccharide. Hybridoma 28:2, 93-99
CrossRef35
Jeremy D. Kimmel, Gregory A. Gibson, Simon C. Watkins, John A. Kellum, William J. Federspiel. (2009) IL-6 adsorption dynamics in hemoadsorption beads studied using confocal laser scanning microscopy. Journal of Biomedical Materials Research Part B: Applied Biomaterials 9999B, NA-NA
CrossRef36
Carlos Mas-Moruno, Laura Cascales, Luis J. Cruz, Puig Mora, Enrique Pérez-Payá, Fernando Albericio. (2008) Nanostructure Formation Enhances the Activity of LPS-Neutralizing Peptides. ChemMedChem 3:11, 1748-1755
CrossRef37
Janet Wittes. 2008. Subgroup. .
CrossRef38
Claire Bellier, Frdric Bert, Franois Durand, Sylvie Retout, Jacques Belghiti, France Mentr, Bruno Fantin. (2008) Risk factors for Enterobacteriaceae bacteremia after liver transplantation. Transplant International 21:8, 755-763
CrossRef39
Raquel Nahra, R Phillip Dellinger. (2008) Targeting the lipopolysaccharides: still a matter of debate?. Current Opinion in Anaesthesiology 21:2, 98-104
CrossRef40
Cynthia M. Otto. (2007) Clinical trials in spontaneous disease in dogs: a new paradigm for investigations of sepsis. Journal of Veterinary Emergency and Critical Care 17:4, 359-367
CrossRef41
Mar Orzáez, Puig Mora, Laura Mondragón, Enrique Pérez-Payá, María J. Vicent. (2007) Solid-phase Chemistry: A Useful Tool to Discover Modulators of Protein Interactions. International Journal of Peptide Research and Therapeutics 13:1-2, 281-293
CrossRef42
Laura Plant, Hong Wan, Ann-Beth Jonsson. (2007) Non-lipooligosaccharide-mediated signalling via Toll-like receptor 4 causes fatal meningococcal sepsis in a mouse model. Cellular Microbiology 9:3, 657-669
CrossRef43
Robert L. Sheridan, Ronald G. Tompkins. 2007. Etiology and prevention of multisystem organ failure. , 434-445.
CrossRef44
A. NORRBY-TEGLUND, K. N. HAQUE, L. HAMMARSTRÖM. (2006) Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. Journal of Internal Medicine 260:6, 509-516
CrossRef45
Jean Carlet. (2006) Early goal-directed therapy of septic shock in the emergency room: Who could honestly remain skeptical?*. Critical Care Medicine 34:11, 2842-2843
CrossRef46
Russell, James A., . (2006) Management of Sepsis. New England Journal of Medicine 355:16, 1699-1713
Full Text47
Germaine Escames, Darío Acuña-Castroviejo, Luis Carlos López, Dun-xian Tan, Maria Dolores Maldonado, Marina Sánchez-Hidalgo, Josefa León, Russel J. Reiter. (2006) Pharmacological utility of melatonin in the treatment of septic shock: experimental and clinical evidence. Journal of Pharmacy and Pharmacology 58:9, 1153-1165
CrossRef48
Kathy Triantafilou, Martha Triantafilou. (2006) Innate recognition of bacteria: potential therapeutic targets for bacterial sepsis. Expert Review of Clinical Immunology 2:5, 787-799
CrossRef49
Suveer Singh, Timothy W. Evans. (2006) Organ dysfunction during sepsis. Intensive Care Medicine 32:3, 349-360
CrossRef50
Thomas A Russo, James R Johnson. (2006) Extraintestinal isolates of Escherichia coli : identification and prospects for vaccine development. Expert Review of Vaccines 5:1, 45-54
CrossRef51
Shinji Kohro, Hitoshi Imaizumi, Michiaki Yamakage, Yoshiki Masuda, Akiyoshi Namiki, Yasuhumi Asai, Ikuo Maruyama. (2006) Anandamide absorption by direct hemoperfusion with polymixin B-immobilized fiber improves the prognosis and organ failure assessment score in patients with sepsis. Journal of Anesthesia 20:1, 11-16
CrossRef52
2006. Monoclonal antibodies. , 2380-2382.
CrossRef53
William R. Clark, Jeffrey J. Letteri, Shigehiko Uchino, Rinaldo Bellomo, Claudio Ronco. (2006) Recent Clinical Advances in the Management of Critically Ill Patients with Acute Renal Failure. Blood Purification 24:5-6, 487-498
CrossRef54
Andres O. Soriano, Wenche Jy, Julio A. Chirinos, Martin A. Valdivia, Hermes S. Velasquez, Joaquin J. Jimenez, Lawrence L. Horstman, Daniel H. Kett, Roland M. H. Schein, Yeon S. Ahn. (2005) Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Critical Care Medicine 33:11, 2540-2546
CrossRef55
M RANGELFRAUSTO. (2005) Sepsis: Still Going Strong. Archives of Medical Research 36:6, 672-681
CrossRef56
Zhi Yuan, Mei Yu, Jihong Li, Guanghui Hou, Huiyan Wang. (2005) Endotoxin adsorbent using dimethylamine ligands. Biomaterials 26:15, 2741-2747
CrossRef57
Takuya Ueno, Michio Sugino, Hiromu Nemoto, Hisataka Shoji, Akira Kakita, Masahiko Watanabe. (2005) Effect Over Time of Endotoxin Adsorption Therapy in Sepsis. Therapeutic Apheresis and Dialysis 9:2, 128-136
CrossRef58
Jonas Sund??n-Cullberg, Anna Norrby-Teglund, Ari Rouhiainen, Heikki Rauvala, Gunilla Herman, Kevin J. Tracey, Martin L. Lee, Jan Andersson, Leif Tokics, Carl Johan Treutiger. (2005) Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock*. Critical Care Medicine 33:3, 564-573
CrossRef59
Andrea Giacometti, Oscar Cirioni, Roberto Ghiselli, Fiorenza Orlando, Wojciech Kamysz, Marco Rocchi, Giuseppina D’Amato, Federico Mocchegiani, Carmela Silvestri, Jerzy Łukasiak, Vittorio Saba, Giorgio Scalise. (2005) Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock. Peptides 26:2, 207-216
CrossRef60
Todd W. Rice, Gordon R. Bernard. (2005) Therapeutic Intervention and Targets for Sepsis*. Annual Review of Medicine 56:1, 225-248
CrossRef61
Vikrant M. Bhor, Celestine J. Thomas, Namita Surolia, Avadhesha Surolia. (2005) Polymyxin B: An ode to an old antidote for endotoxic shock. Molecular BioSystems 1:3, 213
CrossRef62
Djillali Annane, Eric Bellissant, Jean-Marc Cavaillon. (2005) Septic shock. The Lancet 365:9453, 63-78
CrossRef63
Mayumi Fukuyama, Keishi Miwa, Naoko Shibayama, Shinji Ogura, Takashi Nishiyama, Nobuhiro Maekawa. (2005) Mixed Bacterial Infection Model of Sepsis in Rabbits and Its Application to Evaluate Superantigen-Adsorbing Device. Blood Purification 23:2, 119-127
CrossRef64
M. Levi. (2004) Recombinant factor VIIa: a general hemostatic agent? Not yet. Journal of Thrombosis and Haemostasis 2:10, 1695-1697
CrossRef65
Hui Fang, Jiao Wei, YaoTing Yu. (2004) In vivo studies of endotoxin removal by lysine–cellulose adsorbents. Biomaterials 25:23, 5433-5440
CrossRef66
Ryan N. Fiorini, Stephen F. Shafizadeh, Carmen Polito, David W. Rodwell, Gang Cheng, Zachary Evans, Chidan Wan, Sarah Belden, Julia K. Haines, Jennifer Birsner, David Lewin, Karen R. Wasiluk, David L. Dunn, Michael G. Schmidt, Kenneth D. Chavin. (2004) Anti-Endotoxin Monoclonal Antibodies are Protective against Hepatic Ischemia/Reperfusion Injury in Steatotic Mice. American Journal of Transplantation 4:10, 1567-1573
CrossRef67
Guido Grass, Edmund Alwin Martin Neugebauer. (2004) Extracorporeal endotoxin adsorption in septic patients—Does it work?*. Critical Care Medicine 32:8, 1792-1793
CrossRef68
Karen R. Wasiluk, Daniel B. Leslie, Paul S. Vietzen, Kevin H. Mayo, David L. Dunn. (2004) Structure/function studies of an endotoxin-neutralizing peptide derived from bactericidal/permeability-increasing protein. Surgery 136:2, 253-260
CrossRef69
Konrad Reinhart, Andreas Meier-Hellmann, Richard Beale, Helmuth Forst, Dieter Boehm, Sheila Willatts, Karl F. Rothe, Michael Adolph, Joerg E. Hoffmann, Marc Boehme, Donald L. Bredle. (2004) Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected Gram-negative sepsis*. Critical Care Medicine 32:8, 1662-1668
CrossRef70
Kees H Polderman, Armand RJ Girbes. (2004) Drug intervention trials in sepsis: divergent results. The Lancet 363:9422, 1721-1723
CrossRef71
Milo Engoren, Robert H Habib. (2004) Effects of intraaortic balloon augmentation in a porcine model of endotoxemic shock. Resuscitation 60:3, 319-326
CrossRef72
Roberto Ghiselli, Andrea Giacometti, Oscar Cirioni, Federico Mocchegiani, Fiorenza Orlando, Giuseppina DʼAmato, Valerio Sisti, Giorgio Scalise, Vittorio Saba. (2004) Cecropin B Enhances Betalactams Activities in Experimental Rat Models of Gram-Negative Septic Shock. Annals of Surgery 239:2, 251-256
CrossRef73
Christopher James Doig, David A Zygun, Anthony Delaney, Braden J Manns. (2004) Drotrecogin alfa (activated; Xigris®): an effective and cost-efficient treatment for severe sepsis. Expert Review of Pharmacoeconomics & Outcomes Research 4:1, 15-26
CrossRef74
Alan S Cross, Steven Opal, Pamela Cook, Joseph Drabick, Apurba Bhattacharjee. (2004) Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis. Vaccine 22:7, 812-817
CrossRef75
R. Phillip Dellinger, Joseph E. Parrillo. (2004) Mediator modulation therapy of severe sepsis and septic shock: Does it work? *. Critical Care Medicine 32:1, 282-286
CrossRef76
Samuel L. Jones, Anthony T. Blikslager. 2004. Disorders of the Gastrointestinal System. , 769-949.
CrossRef77
James M. O'Brien, Edward Abraham. (2003) New approaches to the treatment of sepsis. Clinics in Chest Medicine 24:4, 521-548
CrossRef78
Alan S Cross, Steven M Opal, John E Palardy, Joseph J Drabick, H.Shaw Warren, Christian Huber, Pamela Cook, Apurba K Bhattacharjee. (2003) Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. Vaccine 21:31, 4576-4587
CrossRef79
J. Carlet. (2003) Drotrecogin Alfa (Activated) Administration: Too Many Subgroups. Critical Care Medicine 31:10, 2564
CrossRef80
Martin A. Russ, H. Bernd Reith. (2003) The Severity of Infection Induces a Shift in the Type 1/Type 2 T-Helper Cell Balance in Patients with or without Peritonitis. Surgical Infections 4:3, 247-254
CrossRef81
Konstantinos Varsamidis, Efterpi Varsamidou, Georgios Mavropoulos. (2003) Doppler ultrasonographic evaluation of hepatic blood flow in clinical sepsis. Ultrasound in Medicine & Biology 29:9, 1241-1244
CrossRef82
Jean-François Dhainaut, Pierre-François Laterre, Steven P. LaRosa, Howard Levy, Gary E. Garber, Darell Heiselman, Gary T. Kinasewitz, R. Bruce Light, Peter Morris, Roland Schein, Jean-Pierre Sollet, Becky M. Bates, Barbara G. Utterback, Dennis Maki. (2003) The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*. Critical Care Medicine 31:9, 2291-2301
CrossRef83
Rhonda S. Fishel, Chandrakanth Are, Adrian Barbul. (2003) Vessel injury and capillary leak. Critical Care Medicine 31:Supplement, S502-S511
CrossRef84
Michael Moncure, Lijun Chen, Ed W. Childs, David Smalley, Kahdi F. Udobi, Laurence Y. Cheung. (2003) Heme-Oxygenase-1 mRNA Expression Affects Hemorrhagic Shock-Induced Leukocyte Adherence. The Journal of Trauma: Injury, Infection, and Critical Care 55:1, 118-125
CrossRef85
Sacha Zeerleder, Bas Zwart, Walter A. Wuillemin, Lucien A. Aarden, A. B. Johan Groeneveld, Christoph Caliezi, Annemarie E. M. van Nieuwenhuijze, Gerard J. van Mierlo, Anke J. M. Eerenberg, Bernhard Lämmle, C. Erik Hack. (2003) Elevated nucleosome levels in systemic inflammation and sepsis*. Critical Care Medicine 31:7, 1947-1951
CrossRef86
Reiner Wiest, Heiko C Rath. (2003) Bacterial translocation in the gut. Best Practice & Research Clinical Gastroenterology 17:3, 397-425
CrossRef87
Jay Steinberg, Jeffrey Halter, Henry J Schiller, Monica Dasilva, Steve Landas, Louis A Gatto, Paivi Maisi, Timo Sorsa, Minna Rajamaki, Hsi-Ming Lee, Gary F Nieman. (2003) Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. Journal of Surgical Research 111:2, 185-195
CrossRef88
David R. Williamson, Marc Lapointe. (2003) The Hypothalamic-Pituitary-Adrenal Axis and Low-Dose Glucocorticoids in the Treatment of Septic Shock. Pharmacotherapy 23:4, 514-525
CrossRef89
Mitchell M. Levy, Mitchell P. Fink, John C. Marshall, Edward Abraham, Derek Angus, Deborah Cook, Jonathan Cohen, Steven M. Opal, Jean-Louis Vincent, Graham Ramsay. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Critical Care Medicine 31:4, 1250-1256
CrossRef90
Edward Abraham, Chris Naum, Venkata Bandi, Daniel Gervich, Stephen F. Lowry, Richard Wunderink, Roland M. Schein, William Macias, Simona Skerjanec, Alex Dmitrienko, Nagy Farid, S. Thomas Forgue, Frank Jiang. (2003) Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Critical Care Medicine 31:3, 718-728
CrossRef91
Timothy E. Albertson, Edward A. Panacek, Rodger D. MacArthur, Steven B. Johnson, Ernest Benjamin, George M. Matuschak, Gary Zaloga, Dennis Maki, Jeffrey Silverstein, Jeffrey K. Tobias, Kathy Haenftling, George Black, J. Wayne Cowens. (2003) Multicenter evaluation of a human monoclonal antibody to Entero-bacteriaceae common antigen in patients with Gram-negative sepsis. Critical Care Medicine 31:2, 419-427
CrossRef92
Michael S. Niederman. (2003) Granulocyte colony-stimulating factor for severe pneumonia: What do we do when the best laid plans for men (and mice and rats…) fail? *. Critical Care Medicine 31:2, 635-637
CrossRef93
Hisataka Shoji. (2003) Extracorporeal Endotoxin Removal For The Treatment of Sepsis:Endotoxin Adsorption Cartridge (Toraymyxin). Therapeutic Apheresis and Dialysis 7:1, 108-114
CrossRef94
Hotchkiss, Richard S., Karl, Irene E., . (2003) The Pathophysiology and Treatment of Sepsis. New England Journal of Medicine 348:2, 138-150
Full Text95
Michael T. Coughlin, Derek C. Angus. (2003) Economic evaluation of new therapies in critical illness. Critical Care Medicine 31:Supplement, S7-S16
CrossRef96
Steven M. Opal, Thomas Glück. (2003) Endotoxin as a drug target. Critical Care Medicine 31:Supplement, S57-S64
CrossRef97
Roberto Ghiselli, Andrea Giacometti, Oscar Cirioni, Federico Mocchegiani, Claudio Viticchi, Giorgio Scalise, Vittorio Saba. (2002) Cationic Peptides Combined with Betalactams Reduce Mortality from Peritonitis in Experimental Rat Model. Journal of Surgical Research 108:1, 107-111
CrossRef98
Christoph Caliezi, Sacha Zeerleder, Maurice Redondo, Bruno Regli, Hans-Ulrich Rothen, Regula Zürcher-Zenklusen, Robert Rieben, Jan Devay, C. Erik Hack, Bernhard Lämmle, Walter A. Wuillemin. (2002) C1-inhibitor in patients with severe sepsis and septic shock: Beneficial effect on renal dysfunction. Critical Care Medicine 30:8, 1722-1728
CrossRef99
Emilio Casariego Vales, Victor Abraira, Juan Carlos Corredoira Sánchez, Marı́a Pilar Alonso Garcı́a, Asunción Rodrı́guez Feijoo, Marı́a José López Alvarez, José Varela Otero, Amparo Coira Nieto, Ramón Rabuñal Rey, Marı́a Teresa Rigueiro Veloso. (2002) A predictive model for mortality of bloodstream infections. Journal of Clinical Epidemiology 55:6, 563-572
CrossRef100
Sadatomo Tasaka, Naoki Hasegawa, Akitoshi Ishizaka. (2002) Pharmacology of Acute Lung Injury. Pulmonary Pharmacology & Therapeutics 15:2, 83-95
CrossRef101
Jürgen Graf, Gordon S. Doig, Deborah J. Cook, Jean-Louis Vincent, William J. Sibbald. (2002) Randomized, controlled clinical trials in sepsis: Has methodological quality improved over time?. Critical Care Medicine 30:2, 461-472
CrossRef102
Michael Heinzelmann, Melanie Scott, Tina Lam. (2002) Factors predisposing to bacterial invasion and infection. The American Journal of Surgery 183:2, 179-190
CrossRef103
Marcel Levi. (2001) Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient. Journal of Critical Care 16:4, 167-177
CrossRef104
E Bölke, P.M Jehle, M Storck, C Braun, S Schams, G Steinbach, K Orth, J Görich, R Scharrer-Pamler, L Sunder-Plassmann. (2001) Endovascular stent-graft placement versus conventional open surgery in infrarenal aortic aneurysm: a prospective study on acute phase response and clinical outcome. Clinica Chimica Acta 314:1-2, 203-207
CrossRef105
Stephen R Ash, Janusz Steczko, Howard Levy, Donald E Blake, David J Carr. (2001) Treatment of Systemic Inflammatory Response Syndrome by Push-Pull Powdered Sorbent Pheresis: A Phase 1 Clinical Trial. Therapeutic Apheresis and Dialysis 5:6, 497-505
CrossRef106
Sunil A. David. (2001) Towards a rational development of anti-endotoxin agents: novel approaches to sequestration of bacterial endotoxins with small molecules. Journal of Molecular Recognition 14:6, 370-387
CrossRef107
Sheridan, Robert L., . (2001) A Great Constitutional Disturbance. New England Journal of Medicine 345:17, 1271-1272
Full Text108
Roberto Ghiselli, Andrea Giacometti, Oscar Cirioni, Fiorenza Orlando, Federico Mocchegiani, Alessandra Mataloni Pacci, Giorgio Scalise, Vittorio Saba. (2001) Therapeutic Efficacy of the Polymyxin-like Peptide Ranalexin in an Experimental Model of Endotoxemia. Journal of Surgical Research 100:2, 183-188
CrossRef109
Heidrun Ullrich, Wolfgang Jakob, Dieter Frohlich, Gregor Rothe, Christopher Prasser, Wolfgang Drobnik, Kai Taeger, Andreas Meier-Hellmann, Konrad Reinhart, Michael Zimmermann, Gerd Schmitz. (2001) A New Endotoxin Adsorber: First Clinical Application. Therapeutic Apheresis and Dialysis 5:5, 326-334
CrossRef110
Tom van der Poll. (2001) Immunotherapy of sepsis. The Lancet Infectious Diseases 1:3, 165-174
CrossRef111
Stephen R. Ash. (2001) Powdered Sorbent Liver Dialysis and Pheresis in Treatment of Hepatic Failure. Therapeutic Apheresis and Dialysis 5:5, 404-416
CrossRef112
Jose M. Martinez, Kristin E. Wagner, Richard H. Snider, Eric S. Nylen, Beat Muller, Babak Sarani, Kenneth L. Becker, Jon C. White. (2001) Late Immunoneutralization of Procalcitonin Arrests the Progression of Lethal Porcine Sepsis. Surgical Infections 2:3, 193-203
CrossRef113
Hidesaku Asakura, Yasuo Ontachi, Tomoe Mizutani, Minori Kato, Takako Ito, Masanori Saito, Eriko Morishita, Masahide Yamazaki, Keiji Aoshima, Akiyoshi Takami, Tomotaka Yoshida, Yukio Suga, Ken-ichi Miyamoto, Shinji Nakao. (2001) Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. European Journal of Haematology 67:3, 170-175
CrossRef114
Andrea Giacometti, Oscar Cirioni, Roberto Ghiselli, Claudio Viticchi, Federico Mocchegiani, Alessandra Riva, Vittorio Saba, Giorgio Scalise. (2001) Effect of mono-dose intraperitoneal cecropins in experimental septic shock. Critical Care Medicine 29:9, 1666-1669
CrossRef115
Denis W. Harkin, Aires A. B. Barros D’Sa, Kevin McCallion, Margaret Hoper, M. Isla Halliday, F. Charles Campbell. (2001) Bactericidal/Permeability-Increasing Protein Attenuates Systemic Inflammation and Acute Lung Injury in Porcine Lower Limb Ischemia–Reperfusion Injury. Annals of Surgery 234:2, 233-244
CrossRef116
Ari Robin Joffe. (2001) Critical Care Medicine: Major Changes in Dogma of the Past Decade. Journal of Intensive Care Medicine 16:4, 177-192
CrossRef117
(2001) Recombinant Human Activated Protein C for Severe Sepsis. New England Journal of Medicine 345:3, 219-221
Full Text118
Olivier Despond, François Proulx, Joseph A. Carcillo, Jacques Lacroix. (2001) Pediatric sepsis and multiple organ dysfunction syndrome. Current Opinion in Pediatrics 13:3, 247-253
CrossRef119
H. Asakura, Y. Ontachi, T. Mizutani, M. Kato, T. Ito, M. Saito, E. Morishita, M. Yamazaki, Y. Suga, K. -I. Miyamoto, S. Nakao. (2001) Depressed plasma activity of plasminogen or α2 plasmin inhibitor is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. Blood Coagulation and Fibrinolysis 12:4, 275-281
CrossRef120
Elliott Bennett-Guerrero, Michael H. Panah, G. Robin Barclay, Carol A. Bodian, Wanda J. Winfree, Lewis A. Andres, David L. Reich, Michael G. Mythen. (2001) Decreased Endotoxin Immunity Is Associated with Greater Mortality and/or Prolonged Hospitalization after Surgery. Anesthesiology 94:6, 992-998
CrossRef121
J.Bruce McClain, Robert Edelman, Moshe Shmuklarsky, John Que, Stanley J Cryz, Alan S Cross. (2001) Unusual persistence in healthy volunteers and ill patients of hyperimmune immunoglobulin directed against multiple Pseudomonas O-chain and Klebsiella serotypes after intravenous infusion. Vaccine 19:25-26, 3499-3508
CrossRef122
Sharmila Foulds, Christine Galustian, Averil O. Mansfield, and Michael Schachter. (2001) Transcription Factor NF??B Expression and Postsurgical Organ Dysfunction. Annals of Surgery 233:1, 70-78
CrossRef123
H. Uronen, A. J. Williams, G. Dixon, S. R. Andersen, P. Van Der Ley, M. Van Deuren, R. E. Callard, N. Klein. (2000) Gram-negative bacteria induce proinflammatory cytokine production by monocytes in the absence of lipopolysaccharide (LPS). Clinical and Experimental Immunology 122:3, 312-315
CrossRef124
Lindsey R. Baden, Barry I. Eisenstein. (2000) Impact of antibiotic resistance on the treatment of gram-negative sepsis. Current Infectious Disease Reports 2:5, 409-416
CrossRef125
David L. Dunn. (2000) Prevention and Treatment of Multiple Organ Dysfunction Syndrome: Lessons Learned and Future Prospects. Surgical Infections 1:3, 227-237
CrossRef126
Masayuki Kawasaki, Kazuyoshi Kuwano, Naoki Hagimoto, Tokuji Matsuba, Ritsuko Kunitake, Takuo Tanaka, Takashige Maeyama, Nobuyuki Hara. (2000) Protection from Lethal Apoptosis in Lipopolysaccharide-Induced Acute Lung Injury in Mice by a Caspase Inhibitor. The American Journal of Pathology 157:2, 597-603
CrossRef127
A KUMAR, C HAERY, J PARRILLO. (2000) MYOCARDIAL DYSFUNCTION IN SEPTIC SHOCK. Critical Care Clinics 16:2, 251-287
CrossRef128
A FEIN, M CALALANGCOLUCCI. (2000) ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME IN SEPSIS AND SEPTIC SHOCK. Critical Care Clinics 16:2, 289-317
CrossRef129
A THOMSON, I GREER. (2000) Non-haemorrhagic obstetric shock. Best Practice & Research Clinical Obstetrics & Gynaecology 14:1, 19-41
CrossRef130
S. Jacobs, S. Sobki, C. Morais, M. Tariq. (2000) Effect of pentaglobin and piperacillin on survival in a rat model of faecal peritonitis: importance of intervention timings. Acta Anaesthesiologica Scandinavica 44:1, 88-95
CrossRef131
Victor Lazaron, Roderick A. Barke. (1999) GRAM-NEGATIVE BACTERIAL SEPSIS AND THE SEPSIS SYNDROME. Urologic Clinics of North America 26:4, 687-699
CrossRef132
Alan S. Cross, Steven M. Opal, Apurba K. Bhattacharjee, Sam T. Donta, Peter N. Peduzzi, Emil Fürer, John U. Que, Stanley J. Cryz. (1999) Immunotherapy of sepsis: flawed concept or faulty implementation?. Vaccine 17, S13-S21
CrossRef133
Carol M. Mason, Steve Nelson. (1999) PULMONARY HOST DEFENSES. Clinics in Chest Medicine 20:3, 475-488
CrossRef134
Grard A.P. Nieuwenhuijzen, R. Jan A. Goris. (1999) The gut: the ‘motor’ of multiple organ dysfunction syndrome?. Current Opinion in Clinical Nutrition and Metabolic Care 2:5, 399-404
CrossRef135
Allan R. Tunkel. (1999) Septic shock and toxic shock: Do adjunctive therapies improve outcome?. Current Infectious Disease Reports 1:3, 215-217
CrossRef136
Todd A. Kellogg, Carl A. Weiss, Jennifer W. Johnston, Karen R. Wasiluk, David L. Dunn. (1999) Antiendotoxin Agents Share Molecular Homology within Their Lipopolysaccharide Binding Domains. Journal of Surgical Research 85:1, 136-141
CrossRef137
LIPING LI, ROBERT G. LUO. (1999) Quantitative Determination of Ca 2+ Effects on Endotoxin Removal and Protein Yield in a Two-Stage Ultrafiltration Process. Separation Science and Technology 34:9, 1729-1741
CrossRef138
Apurba K. Bhattacharjee, Alan S. Cross. (1999) VACCINES AND ANTIBODIES IN THE PREVENTION AND TREATMENT OF SEPSIS. Infectious Disease Clinics of North America 13:2, 355-369
CrossRef139
Jyoti Dhar, Jack N. Losso, John Vanderstoep, Shuryo Nakai. (1999) Separation of Broad Spectrum Anti-LPS IgA From Human Milk Using LPS Chitosan Affinity Chromatography. Food and Agricultural Immunology 11:2, 155-168
CrossRef140
M. Sigfrido Rangel-Frausto. (1999) THE EPIDEMIOLOGY OF BACTERIAL SEPSIS. Infectious Disease Clinics of North America 13:2, 299-312
CrossRef141
Steven M. Opal, Alan S. Cross. (1999) CLINICAL TRIALS FOR SEVERE SEPSIS. Infectious Disease Clinics of North America 13:2, 285-297
CrossRef142
R.Chance DeWitt, Yong Wu, Kathryn B. Renegar, Kenneth A. Kudsk. (1999) Glutamine-Enriched Total Parenteral Nutrition Preserves Respiratory Immunity and Improves Survival to aPseudomonasPneumonia. Journal of Surgical Research 84:1, 13-18
CrossRef143
Judith Hellman, H. Shaw Warren. (1999) ANTIENDOTOXIN STRATEGIES. Infectious Disease Clinics of North America 13:2, 371-386
CrossRef144
C. Wenisch, B. Parschalk, S. Patruta, R. Brustbauer, W. Graninger. (1999) Effect of polyclonal immunoglobulins on neutrophil phagocytic capacity and reactive oxygen production in patients with gram-negative septicemia. Infection 27:3, 183-186
CrossRef145
Janusz Steczko, Stephen R. Ash, Donald E. Blake, David J. Carr, Rebecca H. Bosley. (1999) Cytokines and Endotoxin Removal by Sorbents and Its Application in Push-Pull Sorbent-Based Pheresis: The Biologic-DTPF System. Artificial Organs 23:4, 310-318
CrossRef146
Grard A.P. Nieuwenhuijzen, R. Jan A. Goris. (1999) The gut: the ???motor??? of multiple organ dysfunction syndrome?. Current Opinion in Critical Care 5:2, 126
CrossRef147
Michael Zimmermann, Karin Busch, Stefan Kuhn, Michael Zeppezauer. (1999) Endotoxin Adsorbant Based on Immobilized Human Serum Albumin. Clinical Chemistry and Laboratory Medicine 37:3, 373-379
CrossRef148
Tasnim Sinuff, Deborah J. Cook, John C. Peterson, Hugh D. Fuller. (1999) Development, implementation, and evaluation of a ketoconazole practice guideline for ARDS prophylaxis. Journal of Critical Care 14:1, 1-6
CrossRef149
T Garrett. (1999) Signal transduction triggered by lipid A-like molecules in 70Z/3 pre-B lymphocyte tumor cells. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1437:2, 246-256
CrossRef150
J. N. Moore, Michelle H. Barton. (1999) An update on endotoxaemia Part 2: treatment and the way ahead. Equine Veterinary Education 11:1, 30-34
CrossRef151
R Pararajasingam, M.L Nicholson, P.R.F Bell, R.D Sayers. (1999) Non-cardiogenic Pulmonary Oedema in Vascular Surgery. European Journal of Vascular and Endovascular Surgery 17:2, 93-105
CrossRef152
Stanley A. Nasraway. (1999) Sepsis research. Critical Care Medicine 27:2, 427-430
CrossRef153
Wheeler, Arthur P., Bernard, Gordon R., . (1999) Treating Patients with Severe Sepsis. New England Journal of Medicine 340:3, 207-214
Full Text154
R. Salomão, O. Rigato, A. C. Pignatari, M. A. Freudenberg, C. Galanos. (1999) Bloodstream infections: Epidemiology, pathophysiology and therapeutic perspectives. Infection 27:1, 1-11
CrossRef155
Tohru Tani, Kazuyoshi Hanasawa, Yoshihiro Endo, Toyokazu Yoshioka, Masashi Kodama, Masamitsu Kaneko, Yoshimitsu Uchiyama, Tadao Akizawa, Kodo Takahasi, Katsuo Sugai. (1998) Therapeutic Apheresis for Septic Patients with Organ Dysfunction: Hemoperfusion using a Polymyxin B Immobilized Column. Artificial Organs 22:12, 1038-1044
CrossRef156
Muller Kobold, Mesander, Stegeman, Kallenberg, Cohen Tervaert. (1998) Are circulating neutrophils intravascularly activated in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides?. Clinical and Experimental Immunology 114:3, 491-499
CrossRef157
Gilberto Friedman, Eliezer Silva, Jean-Louis Vincent. (1998) Has the mortality of septic shock changed with time?. Critical Care Medicine 26:12, 2078-2086
CrossRef158
Muller Kobold, Zijlstra, Koene, DE Haas, Kallenberg, Cohen Tervaert. (1998) Levels of soluble FcgammaRIII correlate with disease severity in sepsis. Clinical and Experimental Immunology 114:2, 220-227
CrossRef159
Paul E. Marik, Joseph Varon. (1998) The Management of Sepsis: A Practical Review. Journal of Intensive Care Medicine 13:5, 229-240
CrossRef160
R. Neal Garrison, David A. Spain, Mark A. Wilson, Patricia A. Keelen, Patrick D. Harris. (1998) Microvascular Changes Explain the "Two-Hit" Theory of Multiple Organ Failure. Annals of Surgery 227:6, 851-860
CrossRef161
A. Gikas, G. Samonis, A. Christidou, J. Papadakis, D. Kofteridis, Y. Tselentis, N. Tsaparas. (1998) Gram-negative bacteremia in non-neutropenic patients: A 3-year review. Infection 26:3, 155-159
CrossRef162
Alexander Aledo, Glenn Heller, Leigh Ren, Sharon Gardner, Ira Dunkel, Shelley W. McKay, Carlos Flombaum, Arthur E. Brown. (1998) Septicemia and Septic Shock in Pediatric Patients. Journal of Pediatric Hematology/Oncology 20:3, 215-221
CrossRef163
H. Iwama, T. Komatsu. (1998) Effect of an endotoxin-removing column containing immobilized polymyxin B fiber in a patient with septic shock from gram-positive infection. Acta Anaesthesiologica Scandinavica 42:5, 590-593
CrossRef164
Edward Abraham, Antonio Anzueto, Guillermo Gutierrez, Sidney Tessler, Gerry San Pedro, Richard Wunderink, Anthony Dal Nogare, Stanley Nasraway, Steve Berman, Robert Cooney, Howard Levy, Robert Baughman, Mark Rumbak, R Bruce Light, Lona Poole, Randy Allred, John Constant, James Pennington, Steven Porter. (1998) Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. The Lancet 351:9107, 929-933
CrossRef165
Hisataka Shoji, Tohru Tani, Kazuyoshi Hanasawa, Masashi Kodama. (1998) Extracorporeal Endotoxin Removal by Polymyxin B Immobilized Fiber Cartridge: Designing and Antiendotoxin Efficacy in the Clinical Application. Therapeutic Apheresis and Dialysis 2:1, 3-12
CrossRef166
Samtleben, Bengsch, Boos, Seide. (1998) HELP Apheresis in the Treatment of Sepsis. Artificial Organs 22:1, 43-46
CrossRef167
(1997) What is new in sepsis therapy?. Acta Anaesthesiologica Scandinavica 41, 174-180
CrossRef168
L. C. J. M. Lemaire, J. J. B. van Lanschot, C. P. Stoutenbeek, S. J. H. van Deventer, C. L. Wells, D. J. Gouma. (1997) Bacterial translocation in multiple organ failure: Cause or epiphenomenon still unproven. British Journal of Surgery 84:10, 1340-1350
CrossRef169
Marc E Uknis, Karen R Wasiluk, Robert D Acton, Hans G Klaerner, Peter S Dahlberg, Elena E Ilyina, Judith R Haseman, Beulah H Gray, Kevin H Mayo, David L Dunn. (1997) Design of a potent novel endotoxin antagonist. Surgery 122:2, 380-385
CrossRef170
G. Görtz. (1997) Lokale antiseptische und antiendotoxische Maßnahmen bei intraabdominalen Infektionen. Langenbecks Archiv für Chirurgie 382:S1, S37-S41
CrossRef171
M. G. Davies, P.-O. Hagen. (1997) Systemic inflammatory response syndrome. British Journal of Surgery 84:7, 920-935
CrossRef172
Donald W. Landry, Ginger X.-Q. Yang. (1997) Anti-Cocaine Catalytic Antibodies—A Novel Approach to the Problem of Addiction. Journal of Addictive Diseases 16:3, 1-17
CrossRef173
James Mason, Michael Drummond. (1997) Biotechnology: a special case for health technology assessment?. Health Policy 41:1, 73-81
CrossRef174
R SACHDEVA, K GUNTUPALLI. (1997) ACUTE RESPIRATORY DISTRESS SYNDROME. Critical Care Clinics 13:3, 503-521
CrossRef175
D ANGUS, C SIRIO, G CLERMONT, J BION. (1997) INTERNATIONAL COMPARISONS OF CRITICAL CARE OUTCOME AND RESOURCE CONSUMPTION. Critical Care Clinics 13:2, 389-408
CrossRef176
Warren, H. Shaw, . (1997) Strategies for the Treatment of Sepsis. New England Journal of Medicine 336:13, 952-953
Full Text177
Guillermo Gutierrez. (1997) From the editor. Journal of Critical Care 12:1, 1-2
CrossRef178
Reiner Schaumann, Tilman Schlick, Martin Schaper, Pramod M. Shah. (1997) Is TNF-α a prognostic factor in patients with sepsis?. Clinical Microbiology and Infection 3:1, 24-31
CrossRef179
Karl-Hermann Staubach, Jörg-André Rosenfeldt, Otto Veit, Hans-Peter Bruch. (1997) Extracorporeal Adsorption of Endotoxin. Therapeutic Apheresis and Dialysis 1:1, 67-74
CrossRef180
Kelli M. Bullard, David L. Dunn. (1996) Diagnosis and treatment of bacteremia and intravascular catheter infections. The American Journal of Surgery 172:6, 13s-19s
CrossRef181
Bertrand L. Jaber, Brian J.G. Pereira. (1996) Inflammatory mediators in sepsis: rationale for extracorporeal therapies?. American Journal of Kidney Diseases 28:5, S35-S49
CrossRef182
Fisher, Charles J. Jr., Agosti, Jan M., Opal, Steven M., Lowry, Stephen F., Balk, Robert A., Sadoff, Jerald C., Abraham, Edward, Schein, Roland M.H., Benjamin, Ernest, . (1996) Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein. New England Journal of Medicine 334:26, 1697-1702
Full Text183
P. Vermeij, D. Blok. (1996) New peptide and protein drugs. Pharmacy World and Science 18:3, 87-93
CrossRef184
MARTINA SEIFERT, G. SCHOENHERR, D. ROGGENBUCK, U. MARX, R. von BAEHR. (1996) Generation and Characterization of a Human Monoclonal IgM Antibody That Recognizes a Conserved Epitope Shared by Lipopolysaccharides of Different Gram-Negative Bacteria. Hybridoma 15:3, 191-198
CrossRef185
Kenneth A. Kudsk, Jian Li, Kathryn B. Renegar. (1996) Loss of Upper Respiratory Tract Immunity with Parenteral Feeding. Annals of Surgery 223:6, 629-638
CrossRef186
Clay B. Marsh, Mark D. Wewers. (1996) THE PATHOGENESIS OF SEPSIS. Clinics in Chest Medicine 17:2, 183-197
CrossRef187
David R. Ralston, Roy C. St John. (1996) IMMUNOTHERAPY FOR SEPSIS. Clinics in Chest Medicine 17:2, 307-317
CrossRef188
Michael R. Pinsky. (1996) Organ-specific therapy in critical illness: Interfacing molecular mechanisms with physiological interventions. Journal of Critical Care 11:2, 95-107
CrossRef189
John F. Toney, Margaret M. Parker. (1996) NEW PERSPECTIVES ON THE MANAGEMENT OF SEPTIC SHOCK IN THE CANCER PATIENT. Infectious Disease Clinics of North America 10:2, 239-253
CrossRef190
Arthur P. Wheeler, Gordon R. Bernard. (1996) Applications of molecular biology and biotechnology: antibody therapy of sepsis. Journal of Critical Care 11:2, 77-94
CrossRef191
Curtis N. Sessler, Geoffery L. Bloomfield, Alpha A. Fowler. (1996) CURRENT CONCEPTS OF SEPSIS AND ACUTE LUNG INJURY. Clinics in Chest Medicine 17:2, 213-235
CrossRef192
Shin-ichi Yokota, Hiroshi Ohtsuka, Tsuneo Kohzuki, Hiroshi Noguchi. (1996) A polyreactive human anti-lipid A monoclonal antibody having cross reactivity to polysaccharide portions of Pseudomonas aeruginosa lipopolysaccharides. FEMS Immunology & Medical Microbiology 14:1, 31-38
CrossRef193
Richard C. Prielipp, Douglas B. Coursin, Michael J. Murray. (1996) Recovery Properties of Cisatracurium and Vecuronium in Intensive Care Unit Patients. Anesthesia & Analgesia 82:4, 893
CrossRef194
Bryan G. Garber, Paul C. Hebert, Jean-Denis Yelle, Richard V. Hodder, Jessie MLIS McGowan. (1996) Adult respiratory distress syndrome. Critical Care Medicine 24:4, 687-695
CrossRef195
L. Gianotti, M. Braga, R. Vaiani, F. Almondo, V. Di Carlo. (1996) Experimental gut-derived endotoxaemia and bacteraemia are reduced by systemic administration of monoclonal anti-LPS antibodies. Burns 22:2, 120-124
CrossRef196
M. A. Rogy, H. S. A. Oldenburg, S. Coyle, R. Trousdale, L. L. Moldawer, S. F. Lowry. (1996) Correlation between acute physiology and chronic health evaluation (APACHE) III score and immunological parameters in critically ill patients with sepsis. British Journal of Surgery 83:3, 396-400
CrossRef197
Fabrice Zeni, Pascal Pain, Monique Vindimian, Jean-Pierre Gay, Pierre Gery, Monique Bertrand, Yves Page, Dominique Page, Regine Vermesch, Jean-Claude Bertrand. (1996) Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock. Critical Care Medicine 24:2, 207-214
CrossRef198
K. Someya, Y. Tsutomi, T. Soga, K. Akahane. (1996) A Lipid a Analog Inhibits LPS-Induced Cytokine Expression and Improves Survival in Endotoxemic Mice. Immunopharmacology and Immunotoxicology 18:4, 477-495
CrossRef199
Ramani S. Wonderling, Abdul Ghaffar, Eugene P Mayer. (1996) Lipopolysaccharide-Induced Suppression of Phagocytosis: Effects on the Phagocytic Machinery. Immunopharmacology and Immunotoxicology 18:2, 267-289
CrossRef200
E. Schlichting, T. Aspelin, T. Lyberg. (1996) Interactions of endotoxin with human blood cells and serum proteins. Scandinavian Journal of Clinical & Laboratory Investigation 56:2, 167-176
CrossRef201
Daniel G. Remick. (1995) Applied molecular biology of sepsis. Journal of Critical Care 10:4, 198-212
CrossRef202
Peter K. Linden, Derek C. Angus, Lakshmipathi Chelluri, Robert A. Branch. (1995) The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody. Journal of Critical Care 10:4, 154-164
CrossRef203
A. C. J. Windsor, A. Klava, S. S. Somers, P. J. Guillou, J. V. Reynolds. (1995) Manipulation of local and systemic host defence in the prevention of perioperative sepsis. British Journal of Surgery 82:11, 1460-1467
CrossRef204
I. Salvo, W. Cian, M. Musicco, M. Langer, R. Piadena, A. Wolfler, C. Montani, E. Magni, . (1995) The Italian SEPSIS study: Preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Medicine 21:S2, S244-S249
CrossRef205
L. A. Eidelman, R. Pizov, C. L. Sprung. (1995) New therapeutic approaches in sepsis: A critical review. Intensive Care Medicine 21:S2, S269-S272
CrossRef206
Ian R. Poxton. (1995) Antibodies to lipopolysaccharide. Journal of Immunological Methods 186:1, 1-15
CrossRef207
Terri A. Cavaliere. (1995) Pharmacologic Treatment of Neonatal Sepsis: Antimicrobial Agents and Immunotherapy. Journal of Obstetric, Gynecologic, <html_ent glyph="@amp;" ascii="&"/> Neonatal Nursing 24:7, 647-658
CrossRef208
L. G. THUS. (1995) Clinical trials for the treatment of sepsis. Acta Anaesthesiologica Scandinavica 39, 36-37
CrossRef209
R.A. Barnes. (1995) Immunotherapy and immunoprophylaxis in bone marrow transplantation. Journal of Hospital Infection 30, 223-231
CrossRef210
(1995) Chapter 8: References. APMIS 103:S50, 26-30
CrossRef211
Gregory A. Grant, James A. Russell. (1995) Applied molecular biology: The molecular mechanisms of sepsis. Journal of Critical Care 10:2, 78-81
CrossRef212
E Jones. (1995) Prophylactic anti-lipopolysaccharide freeze-dried plasma in major burns: a double blind controlled trial. Burns 21:4, 267-272
CrossRef213
G. J. McLauchlan, I. D. Anderson, I. S. Grant, K. C. H. Fearon. (1995) Outcome of patients with abdominal sepsis treated in an intensive care unit. British Journal of Surgery 82:4, 524-529
CrossRef214
D. Pittet, S. Rangel-Frausto, N. Li, D. Tarara, M. Costigan, L. Rempe, P. Jebson, R. P. Wenzel. (1995) Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: Incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Medicine 21:4, 302-309
CrossRef215
J.G. Brock-Utne. (1995) Incidence of Gram-negative bacteraemia in sepsis syndrome. Anaesthesia 50:3, 267-268
CrossRef216
Jiri Mayer, Roman Hajek, Jiri Vorlicek, Miroslav Tomiska. (1995) Sepsis and septic shock. Supportive Care in Cancer 3:2, 111-119
CrossRef217
Zenaide M.N. Quezado, Steven M. Banks, Charles Natanson. (1995) New strategies for combatting sepsis: the magic bullets missed the mark…but the search continues. Trends in Biotechnology 13:2, 56-63
CrossRef218
R. F. Kornelisse, R. Groot, H. J. Neijens. (1995) Bacterial meningitis: Mechanisms of disease and therapy. European Journal of Pediatrics 154:2, 85-96
CrossRef219
Kollef, Marin H., Schuster, Daniel P., . (1995) The Acute Respiratory Distress Syndrome. New England Journal of Medicine 332:1, 27-37
Full Text220
J CAVAILLON. (1995) Controversies surrounding current therapies for sepsis syndrome. Bulletin de l'Institut Pasteur 93:1, 21-41
CrossRef221
D Le Roy, C Crouzier, M Dho-Moulin, A-S Dumont, A Bouchet, J.-P Lafont, A Andremont. (1995) Results of passive and active immunization directed against ferric aerobactin in experimental enterobacterial infections in mice and chickens. Research in Microbiology 146:2, 167-174
CrossRef222
David H. Livingston, Edwin A. Deitch. (1995) Multiple Organ Failure: A Common Problem in Surgical Intensive Care Unit Patients. Annals of Medicine 27:1, 13-20
CrossRef223
Philip S. Barie. (1995) Organ-specific support in multiple organ failure: Pulmonary support. World Journal of Surgery 19:4, 581-591
CrossRef224
Leo T. Rosenberg. (1994) Delaying approval of a critical drug: Safety, efficacy, economics, compassion. The Journal of Medical Humanities 15:4, 243-250
CrossRef225
S.C. Donnelly, Colin Robertson. (1994) Mediators, mechanisms and mortality in major trauma. Resuscitation 28:2, 87-92
CrossRef226
LINDA OTT, CRAIG J. McCLAIN, MARK GILLESPIE, BYRON YOUNG. (1994) Cytokines and Metabolic Dysfunction After Severe Head Injury. Journal of Neurotrauma 11:5, 447-472
CrossRef227
Keiji Ishizaki, Yasushi Youda, Duck Mi Yoon, Kenichi Arai, Tatsushi Fujita. (1994) Therapy with antibody to tumor necrosis factor against endotoxin shock in rabbits. Journal of Anesthesia 8:3, 305-310
CrossRef228
Ben A. Van Hout, Maiwenn J. Al, Gilad S. Gordon, Frans F. H. Rutten. (1994) Costs, effects and C/E-ratios alongside a clinical trial. Health Economics 3:5, 309-319
CrossRef229
Sven Muller-Loennies, Otto Holst, Helmut Brade. (1994) Chemical Structure of the Core Region of Escherichia coli J-5 Lipopolysaccharide. European Journal of Biochemistry 224:2, 751-760
CrossRef230
R. T. Patel, K. I. Deen, D. Youngs, J. Warwick, M. R. B. Keighley. (1994) Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. British Journal of Surgery 81:9, 1306-1308
CrossRef231
Stubblefield, Phillip G.Grimes, David A.. (1994) Septic Abortion. New England Journal of Medicine 331:5, 310-314
Full Text232
K. D. FORSYTH. (1994) Host-mediated tissue damage. Journal of Paediatrics and Child Health 30:4, 296-297
CrossRef233
Y. Mizushima, A. Kawasaki, H. Hirata, Y. Daimon, R. Oosaki, S. Morinaga, M. Kobayashi. (1994) An analysis of bacteraemia in a university hospital in Japan over a 10-year period. Journal of Hospital Infection 27:4, 285-298
CrossRef234
G.K.M. Harding, A.R. Ronald. (1994) The management of urinary infections; what have we learned in the past decade?. International Journal of Antimicrobial Agents 4:2, 83-88
CrossRef235
Ruth C. Matthews, James P. Burnie. (1994) Human recombinant antibodies and immunotherapy. FEMS Immunology and Medical Microbiology 9:1, 1-6
CrossRef236
Ch. Brun-Buisson. (1994) The HA-1A saga: The scientific and ethical dilemma of innovative and costly therapies. Intensive Care Medicine 20:5, 314-316
CrossRef237
Helena R. Chang, Keiji Koda, Michael E. McKnight, Mark C. Glassy. (1994) Tumor-associated antigens recognized by human monoclonal antibodies. Annals of Surgical Oncology 1:3, 213-221
CrossRef238
L. M. Bigatello, R. E. Greene, C. L. Sprung, E. A. Panacek, R. C. Straube, J. L. Zimmerman, R. J. Maunder, P. N. Lanken, E. Pile-Spellmann, K. S. Stanek, A. Zaslavsky, W. M. Zapol. (1994) HA-1A in septic patients with ARDS: Results from the pivotal trial. Intensive Care Medicine 20:5, 328-334
CrossRef239
Hirohiko Aoki, Masashi Kodama, Tohru Tani, Kazuyoshi Hanasawa. (1994) Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-inimobilized fiber. The American Journal of Surgery 167:4, 412-417
CrossRef240
D Birk, D Berger, J Limmer, HG Beger. (1994) Is the elimination of endotoxin and cytokines with continuous lavage an alternative procedure in necrotizing enterocolitis?. Acta Paediatrica 83:s396, 24-26
CrossRef241
(1994) The problem of sepsis. Intensive Care Medicine 20:4, 300-304
CrossRef242
A. M. Mello, E. K. J. Pauwels, F. J. Cleton. (1994) Radioimmunotherapy: no news from the newcomer. Journal of Cancer Research and Clinical Oncology 120:3, 121-130
CrossRef243
Stephen C. Schimpff, Daniel A. Scott, James C. Wade. (1994) Infections in cancer patients: some controversial issues. Supportive Care in Cancer 2:2, 94-104
CrossRef244
J. Pugin. (1994) Bacteremia, sepsis and shock. Intensive Care Medicine 20:2, 92-93
CrossRef245
Yehuda L. Danon. (1994) Improvement of Host Defenses with Hemopoietic Growth Factors. Pediatric Hematology-Oncology 11:2, 125-127
CrossRef246
G. Pilz, S. Kääb, K. Werdan, E. Kreuzer. (1994) Evaluation of definitions and parameters for sepsis assessment in patients after cardiac surgery. Infection 22:1, 8-17
CrossRef247
John R. Bradley, David Wilks, David Rubenstein. (1994) The vascular endothelium in septic shock. Journal of Infection 28:1, 1-10
CrossRef248
James J. Rusthoven. (1994) Biological response modifiers and infectious diseases: Actual and potential therapeutic agents. International Journal of Antimicrobial Agents 3:4, 223-243
CrossRef249
Michael J. Boyer, Alison McGeer, Ronald Feld. (1993) Recent advances in the management of infections in cancer patients. Critical Reviews in Oncology/Hematology 15:3, 175-190
CrossRef250
GORDON K. MILLER, GREGORY S. NAEVE, SHAIK A. GAFFAR, ALAN L. EPSTEIN. (1993) Immunologic and Biochemical Analysis of TNT-1 and TNT-2 Monoclonal Antibody Binding to Histones. Hybridoma 12:6, 689-698
CrossRef251
Ann M. Gooding, John F. Bastian, Bradley M. Peterson, Nevin W. Wilson. (1993) Safety and efficacy of intravenous immunoglobulin prophylaxis in pediatric head trauma patients: A double-blind controlled trial. Journal of Critical Care 8:4, 212-216
CrossRef252
Helena R. Chang, Bahman Chavoshan, Henry Park. (1993) Human monoclonal antibody SK1-mediated cytotoxicity against colon cancer cells. Diseases of the Colon & Rectum 36:12, 1152-1157
CrossRef253
Martin T. Corbally. (1993) Supportive care of the paediatric cancer patient. Seminars in Surgical Oncology 9:6, 461-466
CrossRef254
David L. Dunn. (1993) Use of novel therapeutic agents for the treatment of serious infection. The American Journal of Surgery 166:5, 449-455
CrossRef255
Ewa M. Paleolog, Peter Katsikis, Gail Harris, Peter Daddona, Margaret R. Dalesandro, Cheryl S. Kinney, Jim N. Woody, Marc Feldmann. (1993) Antilipid a monoclonal antibody HA-1A decreases the capacity of bacterial lipopolysaccharide to activate human vascular endothelial cells by an immune adherence mechanism. Cytokine 5:6, 570-577
CrossRef256
P. J. Curley, M. J. McMahon, F. Lancaster, R. E. Banks, G. R. Barclay, J. Shefta, A. W. Boylston, J. T. Whicher. (1993) Reduction in circulating levels of CD4-positive lymphocytes in acute pancreatitis: Relationship to endotoxin, interleukin 6 and disease severity. British Journal of Surgery 80:10, 1312-1315
CrossRef257
Gitte Kronborg, T. Pressler, A. Fomsgaard, C. Koch, N. Høiby. (1993) Specific IgG2 antibodies toPseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis. Infection 21:5, 297-302
CrossRef258
S. K. JACKSON, J. PARTON, R. A. BARNES, C. H. POYNTON, C. FEGAN. (1993) Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. European Journal of Clinical Investigation 23:9, 540-545
CrossRef259
Toni Darville, R. Jacobs, B. Giroir. (1993) The systemic inflammatory response syndrome (SIRS): Immunology and potential immunotherapy. Infection 21:5, 279-290
CrossRef260
J. A. Windsor, K. C. H. Fearon, J. A. Ross, G. R. Barclay, E. Smyth, I. Poxton, O. J. Garden, D. C. Carter. (1993) Role of serum endotoxin and antiendotoxin core antibody levels in predicting the development of multiple organ failure in acute pancreatitis. British Journal of Surgery 80:8, 1042-1046
CrossRef261
W. Beck, A. Weckbach. (1993) Nekrotisierende Fasziitis nach geschlossener Beckenringfraktur. Unfallchirurgie 19:4, 234-239
CrossRef262
Alois B. Lang, Emil F�rer, Stanley J. Cryz. (1993) Feasibility of prophylaxis and therapy against Gram-negative infections by human monoclonal antibodies. FEMS Immunology & Medical Microbiology 7:1, 9-13
CrossRef263
Ivan Mitov, Marine Freudenberg, Uwe Bamberger, Chris Galanos. (1993) Cross-binding activity and protective capacity of monoclonal antibodies to lipid A. Immunobiology 188:1-2, 1-12
CrossRef264
Otto HOLST, Sven MULLER-LOENNIES, Buko LINDNER, Helmut BRADE. (1993) Chemical structure of the lipid A of Escherichia coli J-5. European Journal of Biochemistry 214:3, 695-701
CrossRef265
STEPHEN F. LOWRY, LYLE L. MOLDAWER. (1993) Modulation of Cytokine Responses in Sepsis. Annals of the New York Academy of Sciences 685:1 Immunomodulat, 471-482
CrossRef266
Epstein, Franklin H., , Parrillo, Joseph E.. (1993) Pathogenetic Mechanisms of Septic Shock. New England Journal of Medicine 328:20, 1471-1477
Full Text267
Weinberger, Steven E.. (1993) Recent Advances in Pulmonary Medicine. New England Journal of Medicine 328:20, 1462-1470
Full Text268
Wood, Alastair J.J., , Pizzo, Philip A.. (1993) Management of Fever in Patients with Cancer and Treatment-Induced Neutropenia. New England Journal of Medicine 328:18, 1323-1332
Full Text269
Leticia Castillo, Melchor Sanchez. (1993) Septic shock: Pathogenesis and treatment. The Indian Journal of Pediatrics 60:3, 367-379
CrossRef270
J. Sjölin. (1993) Manipulation of the immunoinflammatory reaction in clinical sepsis. Acta Anaesthesiologica Scandinavica 37, 20-24
CrossRef271
Hella-Monika Kuhn. (1993) Cross-reactivity of monoclonal antibodies and sera directed against lipid A and lipopolysaccharides. Infection 21:3, 179-186
CrossRef272
D. Pittet, B. Thiévent, R. P. Wenzel, N. Li, G. Gurman, P. M. Suter. (1993) Importance of pre-existing co-morbidities for prognosis of septicemia in critically ill patients. Intensive Care Medicine 19:5, 265-272
CrossRef273
D.C. Morrison, M.-G. Lei, T. Kirikae, T.-Y. Chen. (1993) Endotoxin receptors on mammalian cells. Immunobiology 187:3-5, 212-226
CrossRef274
Jean-Daniel Baumgartner, Michel-Pierre Glauser. (1993) Immunotherapy of endotoxemia and septicemia. Immunobiology 187:3-5, 464-477
CrossRef275
KEITH A. REIMANN, LINDA C. BURKLY, BEATRICE BURRUS, BARRY C. D. WALTE, CAROL I. LORD, NORMAN L. LETVIN. (1993) In Vivo Administration to Rhesus Monkeys of a CD4-Specific Monoclonal Antibody Capable of Blocking AIDS Virus Replication. AIDS Research and Human Retroviruses 9:3, 199-207
CrossRef276
Leo T. Rosenberg. (1993) We have a prejudice against ourselves?Sentiment, ethics, and reason. The Journal of Medical Humanities 14:1, 5-14
CrossRef277
J. H. F. Shaw, J. B. Koea. (1993) Metabolic basis for management of the septic surgical patient. World Journal of Surgery 17:2, 154-164
CrossRef278
R. G. Molloy, J. A. Mannick, M. L. Rodrick. (1993) Cytokines, sepsis and immunomodulation. British Journal of Surgery 80:3, 289-297
CrossRef279
Nabil S. Dahmash, Mohammed N.H. Chowdhury, Desouky F. Fayed. (1993) Septic shock in critically ill patients: Aetiology, management and outcome. Journal of Infection 26:2, 159-170
CrossRef280
David H. Livingston. (1993) Management of the surgical patient with multiple system organ failure. The American Journal of Surgery 165:2, 8S-13S
CrossRef281
M. Schneemann, G. Schoedon, K. Frei, A. Schaffner. (1993) Immunovascular communication: activation and deactivation of murine endothelial cell nitric oxide synthase by cytokines. Immunology Letters 35:2, 159-162
CrossRef282
Frederick W. Clevenger. (1993) Nutritional support in the patient with the systemic inflammatory response syndrome. The American Journal of Surgery 165:2, 68S-74S
CrossRef283
Hiram C. Polk. (1993) Factors influencing the risk of infection after trauma. The American Journal of Surgery 165:2, 2S-7S
CrossRef284
Ellis S. Caplan. (1993) Role of immunomodulator therapy in sepsis. The American Journal of Surgery 165:2, 20S-25S
CrossRef285
ANDERS FOMSGAARD, IAN ALAN HOLDER. (1993) Effect of a human IgG preparation rich in antibodies to a wide range of lipopolysaccharides on gram-negative bacterial sepsis in burned mice. APMIS 101:1-6, 229-234
CrossRef286
A. C. J. Windsor, P. G. Mullen, A. A. Fowler, H. J. Sugerman. (1993) Role of the neutrophil in adult respiratory distress syndrome. British Journal of Surgery 80:1, 10-17
CrossRef287
T. Lane, D. Smith, E. Wancewicz, R. Funk. (1993) Inhibition of Endotoxin-Mediated Activation of Endothelial Cells by a Perfluorocardon Emulsion. Artificial Cells, Blood Substitutes and Biotechnology 21:2, 163-172
CrossRef288
T.J.J. Inglis, R.W. Lacey, E. Kay, P.M. Hawkey, A. Bodenham, R.T. Calvert. (1993) Monoclonal antiendotoxin agent HA-1A (Centoxin). The Lancet 341:8840, 303
CrossRef289
Richard Horton. (1993) Voluntary suspension of Centoxin. The Lancet 341:8840, 298
CrossRef290
Stephen C. Schimpff. (1993) Gram-negative bacteremia. Supportive Care in Cancer 1:1, 5-18
CrossRef291
Shie-Pon Tzung, Thomas C. Mahl, Peter Lance, Valerie Andersen, Stefan A. Cohen. (1992) Interferon-α prevents endotoxin-induced mortality in mice. European Journal of Immunology 22:12, 3097-3101
CrossRef292
Petter Brandtzaeg, Alfred Halstensen, Peter Kierulf, Terje Espevik, Anders Waage. (1992) Molecular mechanisms in the compartmentalized inflammatory response presenting as meningococcal meningitis or septic shock. Microbial Pathogenesis 13:6, 423-431
CrossRef293
John Ludbrook. (1992) NEW THERAPIES FOR SHOCK ASSOCIATED WITH GRAM-NEGATIVE SEPSIS?. ANZ Journal of Surgery 62:12, 913-915
CrossRef294
Albert F. LoBuglio, Mansoor N. Saleh. (1992) Monoclonal antibody therapy of cancer. Critical Reviews in Oncology/Hematology 13:3, 271-282
CrossRef295
M.A. Woodhead. (1992) Management of pneumonia. Respiratory Medicine 86:6, 459-469
CrossRef296
Jill K. Sherwood, Richard B. Dause, W. Mark Saltzman. (1992) Controlled Antibody Delivery Systems. Bio/Technology 10:11, 1446-1449
CrossRef297
C. R. B. Welbourn, Y. Young. (1992) Endotoxin, septic shock and acute lung injury: Neutrophils, macrophages and inflammatory mediators. British Journal of Surgery 79:10, 998-1003
CrossRef298
J. Reidy, I. Wright, S. J. Boom, R. Barclay, F. DiPadova, G. Ramsay. (1992) Prevention of cardiovascular effects of endotoxaemia by monoclonal antibodies specific for core endotoxin. British Journal of Surgery 79:10, 1087-1090
CrossRef299
(1992) Anti-Endotoxin Monoclonal Antibodies. New England Journal of Medicine 327:12, 889-891
Full Text300
James M. Harkema, Gurdev Singh, Ping Wang, Irshad H. Chaudry. (1992) Pharmacologic agents in the treatment of ischemia, hemorrhagic shock, and sepsis. Journal of Critical Care 7:3, 189-216
CrossRef301
C. Davenport, G.F. Bottazzo, I. Todd. (1992) Stimulation of human B cells specific for Candida albicans for monoclonal antibody production. FEMS Microbiology Letters 89:6, 335-344
CrossRef302
(1992) Patent Evaluation: Protein Fragments as Antibacterial Agents. Expert Opinion on Therapeutic Patents 2:8, 1173-1174
CrossRef303
B. C. M. J. Takx-Köhlen. (1992) Immunomodulators. Pharmaceutisch Weekblad Scientific Edition 14:4, 245-252
CrossRef304
Stephen F. Lowry. (1992) Modulating the metabolic response to injury and infection. Proceedings of the Nutrition Society 51:02, 267-277
CrossRef305
The Intravenous Immunoglobulin Collaborative Study Group . (1992) Prophylactic Intravenous Administration of Standard Immune Globulin as Compared with Core-Lipopolysaccharide Immune Globulin in Patients at High Risk of Postsurgical Infection. New England Journal of Medicine 327:4, 234-240
Full Text306
Joseph T. DiPiro, Robert G. Hamilton, John P. Wei. (1992) Novel antibody drug products. The American Journal of Surgery 164:1, 77-84
CrossRef307
L.C.M. Pallarés, T.W. Evans. (1992) Oxygen transport in the critically ill. Respiratory Medicine 86:4, 289-295
CrossRef308
Swapan K. De, Richard Silverstein, Glen K. Andrews. (1992) Hydrazine sulfate protection against endotoxin lethality: analysis of effects on expression of hepatic cytokine genes and an acute-phase gene. Microbial Pathogenesis 13:1, 37-47
CrossRef309
Albert F. Grootendorst, Eric F.H. van Bommel, Ben van der Hoven, Leo A.M.G. van Leengoed, Gonnie A.L.M. van Osta. (1992) High-volume hemofiltration improves hemodynamics of endotoxin-induced shock in the pig. Journal of Critical Care 7:2, 67-75
CrossRef310
Kevin J. Inman, Claudio M. Martin, William J. Sibbald. (1992) Design and conduct of clinical trials in critical care. Journal of Critical Care 7:2, 118-128
CrossRef311
M. C. Nahata. (1992) Advances in paediatric pharmacotherapy. Journal of Clinical Pharmacy and Therapeutics 17:3, 141-146
CrossRef312
William J. Sibbald, Kevin J. Inman. (1992) Problems in Assessing the Technology of Critical Care Medicine. International Journal of Technology Assessment in Health Care 8:03, 419
CrossRef313
David B Gough. (1992) Overview: Exploitation of the Contrasting Immunomodulatory Characteristics of Interleukin-2 - A Review and Comment on Recent Patent Literature. Expert Opinion on Therapeutic Patents 2:6, 871-881
CrossRef314
R. Függer, M. Rogy, S. Klimann, M. Prager, E. Kyral, G. Hamilton, F. Schulz. (1992) Endotoxin, TNFa und IL-6 bei abdomineller Sepsis. European Surgery 24:3, 174-179
CrossRef315
Warren, H. Shaw, , Danner, Robert L., , Munford, Robert S., . (1992) Anti-Endotoxin Monoclonal Antibodies. New England Journal of Medicine 326:17, 1153-1157
Full Text316
Wenzel, Richard P., . (1992) Anti-Endotoxin Monoclonal Antibodies — A Second Look. New England Journal of Medicine 326:17, 1151-1153
Full Text317
(1992) Anti-Endotoxin Monoclonal Antibodies. New England Journal of Medicine 326:17, 1165-1165
Full Text318
RonaldH.W Lorijn. (1992) Monoclonal endotoxin antibody in meningococcal sepsis. The Lancet 339:8798, 930-931
CrossRef319
Carolyn S. Cody, Randall S. Burd, Jaime L. Mayoral, David L. Dunn. (1992) Protective anti-lipopolysaccharide monoclonal antibodies inhibit tumor necrosis factor production. Journal of Surgical Research 52:4, 314-319
CrossRef320
Carol M. Mason, Warren R. Summer, Steve Nelson. (1992) Pathophysiology of pulmonary defense mechanisms. Journal of Critical Care 7:1, 42-46
CrossRef321
Simon Nadel, Nigel Klein, Robert Heyderman, Michael Levin. (1992) Endotoxin antibody for sepsis in infants. The Lancet 339:8794, 678
CrossRef322
Hiram C. Polk, William G. Cheadle, David H. Livingston, Jorge L. Rodriguez, Karen M. Starko, Allen E. Izu, Howard S. Jaffe, Gerald Sonnenfeld. (1992) A randomized prospective clinical trial to determine the efficacy of interferon-γ in severely injured patients. The American Journal of Surgery 163:2, 191-196
CrossRef323
S.A. Syed, R.H. Taylor, P.M. Crean, R.J. Stewart. (1992) Successful use of monoclonal anti-lipid-A IgM in infant with meningococcal sepsis. The Lancet 339:8791, 496
CrossRef324
P.D Macnaughton, T.W Evans. (1992) Management of adult respiratory distress syndrome. The Lancet 339:8791, 469-472
CrossRef325
Yuji HAISHIMA, Otto HOLST, Helmut BRADE. (1992) Structural investigation on the lipopolysaccharide of Escherichia coli rough mutant F653 representing the R3 core type. European Journal of Biochemistry 203:1-2, 127-134
CrossRef326
J.S. Hogan, D.A. Todhunter, G.M. Tomita, K.L. Smith, P.S. Schoenberger. (1992) Opsonic Activity of Bovine Serum and Mammary Secretion After Escherichia coli J5 Vaccination. Journal of Dairy Science 75:1, 72-77
CrossRef327
T.J. Wilkinson, B.A. Robinson. (1992) Neutropenic sepsis complicating treatment of solid tumours, lymphoma and myeloma. Clinical Oncology 4:6, 355-361
CrossRef328
T. Lane, D. Smith, E. Wancewicz, R. Funk. (1992) Inhibition of Endotoxin-Mediated Activation of Endothelial Cells by a Perfluorocarbon Emulsion. Artificial Cells, Blood Substitutes and Biotechnology 20:2-4, 1051-1057
CrossRef329
Gerhard Hamilton, Susanne Hofbauer, Barbara Hamilton. (1992) Endotoxin, TNF-alpha, Interleukin-6 and Parameters of the Cellular Immune System in Patients with Intraabdominal Sepsis. Scandinavian Journal of Infectious Diseases 24:3, 361-368
CrossRef330
Flier, Jeffrey S., Underhill, Lisa H., Wilmore, Douglas W., . (1991) Catabolic Illness. New England Journal of Medicine 325:10, 695-702
Full Text331
J. Cohen, M.P. Glauser. (1991) Septic shock: treatment. The Lancet 338:8769, 736-739
CrossRef332
John William Christman, Arthur P. Wheeler, Gordon R. Bernard. (1991) Cytokines and sepsis: What are the therapeutic implications?. Journal of Critical Care 6:3, 172-182
CrossRef333
JOHN L HOLMES, PAUL W PEAKE. (1991) Rapidly progressive and overwhelming meningococcal septicaemia in a 14 year old girl. Emergency Medicine 3:3, 97-100
CrossRef334
(1991) The HA-1A Monoclonal Antibody for Gram-Negative Sepsis. New England Journal of Medicine 325:4, 279-283
Full Text335
Oates, John A., Wood, Alastair J.J., , Buckley, Rebecca H., Schiff, Richard I., . (1991) The Use of Intravenous Immune Globulin in Immunodeficiency Diseases. New England Journal of Medicine 325:2, 110-117
Full Text336
Ruurd Torensma, Ad Fluit. (1991) Mechanism for monoclonal antibody mediated treatment of gram-negative shock. The Lancet 338:8760, 186
CrossRef337
Victor S. Blanchette, Ronald A. Sacher. (1991) Guest Editorial: Intravenous Immunoglobulin: More Questions Than Answers. Transfusion Medicine Reviews 5:3, 165-170
CrossRef338
G. Pilz, S. Kääb, K. Werdan, Gertraud Neeser, Isolde Class, Ursula Schweigart, A. Brähler, O. Bujdoso, Roswita Neumann. (1991) Supplemental immunoglobulin (ivIgG) treatment in 163 patients with sepsis and septic shock — An observational study as a prerequisite for placebo-controlled clinical trials. Infection 19:4, 216-227
CrossRef339
Paul Lehner, Jonathan Cohen, EdwardK. Chapnick, LarryI. Lutwick, H.S. Boardman. (1991) Monoclonal antibody HA-1A for gram-negative shock. The Lancet 337:8748, 1036-1037
CrossRef340
D. Journois, D. Chanu, D. Safran, Alain Wynckel, Olivier Toupance, Tony Wong, Jacques Chanard, Richard Beale, David Bihari. (1991) Pump-driven haemofiltration. The Lancet 337:8747, 985-986
CrossRef341
Wolff, Sheldon M., . (1991) Monoclonal Antibodies and the Treatment of Gram-Negative Bacteremia and Shock. New England Journal of Medicine 324:7, 486-488
Full Text
- Letters
